Fused ring compound, and preparation method therefor and use thereof
By designing novel fused-ring compounds and antibody-drug conjugates, the problems of insufficient stability and targeting of bioactive molecules in existing ADCs have been solved, achieving efficient killing of tumor cells and protection of normal cells, thus improving the therapeutic efficacy and safety of ADCs.
Patent Information
- Application Number
- PCT/CN2024/092336
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-27
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
Among existing antibody-drug conjugates (ADCs), bioactive molecules such as microtubule inhibitors have problems with insufficient stability, uniformity, hydrophilicity and safety when killing cancer cells, making it difficult to effectively target tumor cells and reduce damage to normal tissues.
A novel fused-ring compound with excellent antitumor activity was developed for the preparation of antibody-drug conjugates (ADCs). By linking the ADC with an antibody, the stability, homogeneity, and hydrophilicity of the bioactive molecule were improved, thereby enhancing its targeting and selective killing ability against tumor cells.
This study achieved efficient release and killing of antibody-drug conjugates in tumor cells, reduced damage to normal cells, improved the stability, uniformity, and safety of ADCs, and enhanced the therapeutic effect on tumors.
Smart Images

Figure PCTCN2024092336-FTAPPB-I100001 
Figure PCTCN2024092336-FTAPPB-I100002 
Figure PCTCN2024092336-FTAPPB-I100003
Abstract
Description
Condensed ring compound and its preparation method and use
[0001] This application is based on the application with CN application number 202310538792.7 and application date May 12, 2023, and the application with CN application number 202311413460.2 and application date October 27, 2023, and claims their priority. The disclosed contents of these applications are hereby introduced into this application as a whole. Technical Field
[0002] The present application relates to the field of medicine, and in particular to a fused ring compound and a preparation method and use thereof. Background Art
[0003] Antibody drug conjugates (ADCs) typically consist of a monoclonal antibody, a bioactive molecule (primarily a tumor-killing cytotoxin), and a linker. The bioactive molecule is covalently coupled to the antibody via the linker. The antibody recognizes specific targets on the surface of tumor cells, guiding the ADC to the tumor microenvironment and the surface of cancer cells, where it enters the cancer cells through endocytosis. The bioactive molecule is then released inside the cancer cells and kills them by inhibiting their microtubules or damaging their DNA, minimizing damage to normal tissue cells.
[0004] Bioactive molecules suitable for ADCs mainly include anti-tubulin agents, DNA intercalators, DNA topoisomerase inhibitors, RNA polymerase inhibitors, and gene transcription inhibitors. Currently, the toxins used in ADCs sold on the market and in clinical trials are mainly microtubule inhibitors, such as MMAE, MMAF, DM1, and DM4.
[0005] The present invention aims to provide a novel fused-ring compound with excellent anti-tumor activity and is suitable for preparing antibody-drug conjugates (ADCs). The conjugates have good stability, homogeneity, hydrophilicity, efficacy, and safety.
[0006] Summary of the Invention
[0007] Compound
[0008] In a first aspect, the present invention provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein the compound has the structure shown in the following formula (I):
[0009] in, Indicates a single bond or no chemical bond;
[0010] R1, R2, R3, R4, R6 and R7 are each independently selected from hydrogen, -CN, halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1- 6 alkyl)2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl groups are optionally substituted by one or more selected from -CN, halogen, -OH, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 substituted by aryl and 5-10 membered heteroaryl substituents;
[0011] R5 is -(C=O)-D2-D3-X6, wherein D2 is -O-, -S- or -NR X -, where R X is hydrogen or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more radicals selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2 and -CN substituents; D3 is C 1-6 Alkylene, C 2-6 Alkenylene or C 2-6 Alkyne; the alkylene, alkenylene and alkynylene are optionally substituted by one or more selected from -CN, halogen, -OH, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 substituted by aryl and 5-10 membered heteroaryl substituents; X6 is selected from hydrogen, halogen, -OH, C 1-6 Alkoxy, -SH, -SC 1-6 Alkyl, -NH2, -NH(C 1-6 alkyl) and -N(C 1-6 Alkyl) 2, the C 1-6 The alkyl group is optionally substituted with one or more radicals selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C1-6 Alkyl)2, -CN and C 1-6 Substitution of alkoxy groups;
[0012] Y1 and Y2 are each independently -C(R8)2-, wherein R8 are each independently selected from hydrogen, -CN, halogen, -OH, -NH2, -NH(C 1- 6 alkyl), -N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6- 10 Aryl and 5-10 membered heteroaryl, or two R8 attached to the same carbon atom together form =O;
[0013] X1, X2 and X5 are each independently selected from substituted or unsubstituted C 1-6 Alkylene, -O-, -NR Y - and -S-; among which R Y Each occurrence is independently selected from hydrogen or optionally substituted by one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2 and -CN substituted C 1-6 alkyl;
[0014] when When it represents a single bond, X4 is selected from substituted or unsubstituted C 1-6 Alkylene, -O-, -NR Y - and -S-; among which R Y Each occurrence is independently selected from hydrogen or optionally substituted by one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2 and -CN substituted C 1-6 alkyl;
[0015] when When there is no chemical bond, X4 is selected from substituted or unsubstituted C 1-6 Alkyl, -OR Y 、-N(R Y )2 and -S-; wherein R Y Each occurrence is independently selected from hydrogen or optionally substituted by one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2 and -CN substituted C 1-6alkyl;
[0016] X3 for CR Z or N, where R Z is hydrogen or optionally substituted by one or more halogens, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2 and -CN substituted C 1-6 alkyl;
[0017] And, when When it represents a single bond, R1 and R7 are methoxy, R2, R3, and R4 are all hydroxyl, Y1 and Y2 are all -(C=O)-, X1, X2, X4, and X5 are all O, X3 is N, D2 is NH, and D3 is ethylene, X6 is not NH2.
[0018] In some embodiments, R1, R2, R3, R4, R6 and R7 are each independently selected from hydrogen, -CN, halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy; the alkyl, alkoxy is optionally one or more selected from -CN, halogen, -OH, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 substituted by aryl and 5-10 membered heteroaryl substituents.
[0019] In some embodiments, R1, R2, R3, R4, R6 and R7 are each independently selected from hydrogen, -OH, C 1-6 Alkyl and C 1-6 Alkoxy; the alkyl, alkoxy is optionally one or more selected from -CN, halogen, -OH, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 substituted by aryl and 5-10 membered heteroaryl substituents.
[0020] In some embodiments, R1, R2, R3, R4, R6 and R7 are each independently selected from hydrogen, -OH and C 1-6 Alkoxy; the alkoxy is optionally substituted by one or more selected from -CN, halogen, -OH, -NH2, C 1-6Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 substituted by aryl and 5-10 membered heteroaryl substituents.
[0021] In some embodiments, R1, R2, R3, R4, R6 and R7 are each independently selected from hydrogen, -OH, C 1-6 Alkyl and C 1-6 Alkoxy.
[0022] In some embodiments, R1, R2, R3, R4, R6 and R7 are each independently selected from hydrogen, -OH and C 1-6 Alkoxy.
[0023] In some embodiments, R2, R3, and R4 are all -OH.
[0024] In some embodiments, R1 and R7 are each independently selected from C 1-6 Alkoxy, such as methoxy, ethoxy, n-propoxy or isopropoxy. In some embodiments, R1 and R7 are both methoxy.
[0025] In some embodiments, R6 is selected from C 1-6 Alkyl, such as methyl, ethyl, n-propyl or isopropyl. In some embodiments, R6 is methyl.
[0026] In some embodiments, R1 and R7 are both methoxy; R2, R3, and R4 are all -OH; and R6 is methyl.
[0027] In some embodiments, R5 is -(C=O)-D2-D3-X6, wherein D2 is -O-, -S- or -NR X -, where R X is hydrogen or C 1-6 Alkyl; D3 is C 1-6 Alkylene; the alkylene is optionally substituted by one or more selected from -CN, halogen, -OH, -NH2, C 1-6 Alkyl, C 1- 6 alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 substituted by aryl and 5-10 membered heteroaryl substituents; X6 is selected from -OH, C 1-6 Alkoxy, -SH, -SC 1-6 Alkyl, -NH2, -NH(C 1-6 alkyl) and -N(C 1-6Alkyl) 2, the C 1-6 The alkyl group is optionally substituted with one or more radicals selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -CN and C 1-6 The substituents of the alkoxy group are substituted.
[0028] In some embodiments, R5 is -(C=O)-D2-D3-X6, wherein D2 is -O-, -S- or -NR X -, where R X is hydrogen or C 1-6 Alkyl; D3 is C 1-6 Alkylene; X6 is selected from -OH, C 1-6 Alkoxy, -SH, -SC 1-6 Alkyl, -NH2, -NH(C 1-6 alkyl) and -N(C 1- 6 alkyl)2.
[0029] In some embodiments, R5 is -(C=O)-D2-D3-X6, wherein D2 is -O-, -S- or -NR X -, where R X Selected from hydrogen, methyl and ethyl; D3 is selected from methylene, ethylene, -(CH2)3, -CH2-CH(CH3)- and -CH2-C(CH3)2-; X6 is selected from -OH, methoxy, ethoxy, -SH, -S-CH3, -NH2, -NH(CH3) and -N(CH3)2.
[0030] In some embodiments, R5 is -(C=O)-D2-D3-X6, wherein D2 is selected from -O-, -S-, -NH- and -N(CH3)-; D3 is selected from methylene, ethylene, -(CH2)3, -CH2-CH(CH3)- and -CH2-C(CH3)2-; and X6 is selected from -OH, methoxy, ethoxy, -SH, -S-CH3, -NH2, -NH(CH3) and -N(CH3)2.
[0031] In some embodiments, R5 is selected from:
[0032] In some embodiments, Y1 and Y2 are each independently -C(R8)2-, wherein R8 are each independently selected from hydrogen, -CN, halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, or two R8 attached to the same carbon atom together form =O;
[0033] Preferably, Y1 and Y2 are both -(C=O)-.
[0034] In some embodiments, X1, X2, X4 and X5 are each independently selected from substituted or unsubstituted C 1-6 Alkylene, -O- or -NR Y ; where R Y Each occurrence is independently selected from hydrogen or optionally substituted by one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1- 6 alkyl) 2 and -CN substituted C 1-6 alkyl;
[0035] Preferably, X1, X2, X4 and X5 are all -O-.
[0036] In some embodiments, when When it represents a single bond, X4 is a substituted or unsubstituted C 1-6 Alkylene or -O-; preferably, X4 is selected from -O-.
[0037] In some embodiments, when When there is no chemical bond, X4 is a substituted or unsubstituted C 1-6 Alkyl or -OR Y ; where R Y Each occurrence is independently selected from hydrogen or optionally substituted by one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2 and -CN substituted C 1-6 Alkyl; preferably, X4 is selected from -OH.
[0038] In some embodiments, X3 is CR Z or N, where R Z is selected from hydrogen or C optionally substituted by one or more substituents selected from halogen, -OH, -NH2 and -CN 1-6 alkyl.
[0039] In some embodiments, X3 is N.
[0040] In some embodiments, the compound has a structure as shown in the following formula (III)-1 or (III)-2:
[0041] wherein X1 to X5, R1 to R7, Y1 and Y2 are as described above.
[0042] In some embodiments, the compound has a structure as shown in the following formula (IV)-1 or (IV)-2:
[0043] Wherein, R5 is as described above.
[0044] In some embodiments, the compound has a structure as shown in the following formula (V)-1 or (V)-2:
[0045] Wherein, R5 is as described above.
[0046] All technical features disclosed in this specification, except for mutually exclusive technical features, can be combined in any manner.
[0047] The present invention encompasses compounds resulting from any combination of the various embodiments.
[0048] In some embodiments, the compound is selected from the following structures:
[0049] Antibody Drug Conjugates
[0050] The fused ring compounds of the present invention have excellent anti-tumor activity and are suitable for preparing antibody-drug conjugates. In some embodiments, the resulting antibody-drug conjugates have good stability, homogeneity, hydrophilicity, efficacy, and safety.
[0051] Therefore, in another aspect, the present application provides an antibody drug conjugate containing any one of the compounds described above or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite or prodrug fragment thereof.
[0052] Pharmaceutical composition
[0053] In another aspect, the present application provides a pharmaceutical composition comprising a compound as described above or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite or prodrug or antibody-drug conjugate thereof, and one or more pharmaceutical excipients.
[0054] The compounds or antibody drug conjugates described herein are typically formulated in a unit injectable form together with a pharmaceutically acceptable parenteral vehicle for parenteral use, such as bolus injection, intravenous injection, intratumoral injection, etc. Optionally, the antibody drug conjugate having the desired purity is mixed with a pharmaceutically acceptable diluent, carrier, excipient or stabilizer in the form of a lyophilized agent or solution (Remington's Pharmaceutical Sciences (1980) 16 thAdministration of the compounds or antibody drug conjugates described herein, or pharmaceutical compositions containing the same, can be by any route appropriate to the subject to be treated.
[0055] application
[0056] The compounds described herein or pharmaceutical compositions thereof can be used to treat a variety of diseases or conditions, such as cancer or tumors.
[0057] Therefore, the present application provides the use of any of the above-described compounds or their pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, nitrogen oxides, isotope labels, metabolites or prodrugs, or pharmaceutical compositions thereof in the preparation of drugs for treating cancer or tumors.
[0058] At the same time, the present application provides the compound described in any of the foregoing or its pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite or prodrug, or its pharmaceutical composition, and its use in drugs for treating cancer or tumors.
[0059] At the same time, the present application also provides a method for treating cancer or tumors, which comprises the step of administering to a subject in need thereof an effective amount of any of the compounds described above or its pharmaceutically acceptable salts, esters, stereoisomers, polymorphs, solvates, nitrogen oxides, isotope labels, metabolites or prodrugs, or a pharmaceutical composition containing the same.
[0060] In some embodiments, the cancer or tumor includes solid tumors and hematologic malignancies, such as urothelial carcinoma, gastric cancer, breast cancer, lung cancer (e.g., non-small cell lung cancer, particularly lung adenocarcinoma), or lymphoma.
[0061] In some embodiments, the compound or pharmaceutical composition thereof is sufficient (e.g., in a subject):
[0062] (1) Inhibit cell (such as tumor cell) proliferation;
[0063] (2) inhibit tumor growth; or
[0064] (3) induce and / or increase antibody-dependent cellular cytotoxicity activity;
[0065] (4) Any combination of (1) to (3) above.
[0066] definition
[0067] Unless otherwise defined below, the meanings of all technical and scientific terms used herein are intended to be the same as those generally understood by those skilled in the art. Reference to the techniques used herein is intended to refer to techniques generally understood in the art, including variations of those techniques that are obvious to those skilled in the art or replacements with equivalent techniques. Furthermore, laboratory procedures such as genomics, nucleic acid chemistry, and molecular biology used herein are conventional procedures widely used in the corresponding fields. Although it is believed that the following terms are well understood by those skilled in the art, the following definitions are still set forth to better explain the present invention.
[0068] The term "antibody" refers to an immunoglobulin molecule typically composed of two pairs of polypeptide chains, each pair having one light chain (LC) and one heavy chain (HC). Antibody light chains can be classified as kappa (κ) and lambda (λ) light chains. Heavy chains can be classified as μ, δ, γ, α, or ε, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within light and heavy chains, the variable and constant regions are connected by a "J" region of approximately 12 or more amino acids, with heavy chains also containing a "D" region of approximately 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region is composed of three domains: CH1, CH2, and CH3. Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region is composed of one domain, CL. The constant domains are not directly involved in the binding of antibodies to antigens, but exhibit a variety of effector functions, such as mediating the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The VH and VL regions can also be subdivided into regions of high variability, called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions (VH and VL) of each heavy chain / light chain pair form the antigen binding site, respectively. The allocation of amino acids in each region or domain can follow various numbering systems known in the art.
[0069] The term "complementarity determining region" or "CDR" refers to the amino acid residues in the variable region of an antibody that are responsible for antigen binding. The variable regions of the heavy and light chains each contain three CDRs, designated CDR1, CDR2, and CDR3. The precise boundaries of these CDRs can be defined according to various numbering systems known in the art, for example, as defined in the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al. (1989) Nature 342:878-883), the IMGT numbering system (Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003), or the AbM numbering system (Martin ACR, Cheetham JC, Rees AR (1989) Modelling antibody hypervariable loops: A combined algorithm. Proc Natl Acad Sci USA 86:9268-9272). For a given antibody, a person skilled in the art will readily identify the CDRs defined by each numbering system. Furthermore, the correspondence between different numbering systems is well known to those skilled in the art (e.g., see Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003).
[0070] In the present invention, the CDRs contained in an antibody or antigen-binding fragment thereof can be determined according to various numbering systems known in the art, such as those defined by the Kabat, Chothia, IMGT, or AbM numbering systems. In certain embodiments, the CDRs contained in an antibody or antigen-binding fragment thereof are defined by the Chothia numbering system.
[0071] The term "framework region" or "FR" residues refers to those amino acid residues in the variable region of an antibody other than the CDR residues as defined above.
[0072] The term "antigen-binding fragment" of an antibody refers to polypeptides that are fragments of an antibody, such as polypeptides that are fragments of a full-length antibody, which retain the ability to specifically bind to the same antigen bound by the full-length antibody and / or compete with the full-length antibody for specific binding to the antigen, and are also referred to as "antigen-binding portions." See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Antigen-binding fragments of antibodies can be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Non-limiting examples of antigen-binding fragments include Fab fragments, Fab' fragments, F(ab)'2 fragments, F(ab)'3 fragments, Fd, Fv, scFv, di-scFv, (scFv)2, disulfide-stabilized Fv proteins ("dsFv"), single domain antibodies (sdAbs, nanobodies), and polypeptides that comprise at least a portion of an antibody sufficient to confer specific antigen-binding ability on the polypeptide. Engineered antibody variants are reviewed in Holliger et al., 2005; Nat Biotechnol, 23: 1126-1136.
[0073] The term "Fd" means an antibody fragment consisting of the VH and CH1 domains; the term "dAb fragment" means an antibody fragment consisting of the VH domain (Ward et al., Nature 341:544-546 (1989)); the term "Fab fragment" means an antibody fragment consisting of the VL, VH, CL and CH1 domains; the term "F(ab')2 fragment" means an antibody fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; the term "Fab' fragment" means a fragment obtained after reducing the disulfide bonds linking the two heavy chain fragments in the F(ab')2 fragment, consisting of one complete light chain and the Fd fragment (consisting of the VH and CH1 domains) of the heavy chain.
[0074] The term "Fv" refers to an antibody fragment consisting of the VL and VH domains of a single arm of an antibody. The Fv fragment is generally considered to be the smallest antibody fragment that can form a complete antigen-binding site. It is generally believed that the six CDRs confer antigen-binding specificity to an antibody. However, even a single variable region (e.g., an Fd fragment, which contains only three CDRs specific for an antigen) can recognize and bind to an antigen, although its affinity may be lower than that of the complete binding site.
[0075] The term "Fc" refers to an antibody fragment formed by disulfide bonds between the second and third constant regions of the first heavy chain and the second and third constant regions of the second heavy chain. The Fc fragment of an antibody has various functions but is not involved in antigen binding.
[0076] The term "scFv" refers to a single polypeptide chain comprising a VL and VH domain, wherein the VL and VH are connected by a linker (see, e.g., Bird et al., Science 242: 423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85: 5879-5883 (1988); and Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, Roseburg and Moore, eds., Springer-Verlag, New York, pp. 269-315 (1994)). Such scFv molecules may have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof. For example, a linker having the amino acid sequence (GGGGS)4 can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448). Other linkers useful in the present invention are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56, and Roovers et al. (2001), Cancer Immunol. In some cases, a disulfide bond may also be present between the VH and VL of the scFv. In certain embodiments, the VH and VL domains may be positioned relative to each other in any suitable arrangement. For example, a scFv comprising NH2-VH-VH-COOH, NH2-VL-VL-COOH.
[0077] The term "single-domain antibody (sdAb)" has the meaning generally understood by those skilled in the art, and refers to an antibody fragment composed of a single monomeric variable antibody domain (e.g., a single heavy chain variable region) that retains the ability to specifically bind to the same antigen as the full-length antibody (Holt, L. et al., Trends in Biotechnology, 21(11):484-490, 2003). Single-domain antibodies are also called nanobodies.
[0078] Each of the above antibody fragments retains the ability to specifically bind to the same antigen as the full-length antibody, and / or competes with the full-length antibody for specific binding to the antigen.
[0079] Herein, unless the context clearly indicates otherwise, when referring to the term "antibody", it includes not only intact antibodies, but also antigen-binding fragments of antibodies.
[0080] Antigen-binding fragments of antibodies (e.g., those described above) can be obtained from a given antibody (e.g., an antibody provided herein) using conventional techniques known to those skilled in the art (e.g., recombinant DNA technology or enzymatic or chemical cleavage methods), and the antigen-binding fragments of antibodies can be screened for specificity in the same manner as for intact antibodies.
[0081] The twenty conventional amino acids referred to herein are denoted according to conventional usage. See, for example, Immunology—A Synthesis (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. In the present invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.
[0082] The term "linker" refers to a structural fragment that connects a cytotoxic drug to an antibody or antigen-binding fragment.
[0083] The term "drug-linker" refers to the structure of the cytotoxic drug and linker described herein before being linked to the antibody or antigen-binding fragment thereof. The "drug-linker" is covalently linked to the antibody or antigen-binding fragment thereof to form the antibody-drug conjugate described herein.
[0084] The "drug-linker" also includes all pharmaceutically acceptable isotope-labeled compounds thereof, which are identical to the "drug-linker" compounds of the present invention except that one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number prevalent in nature. Examples of isotopes suitable for inclusion in the present invention include, but are not limited to, isotopes of hydrogen (e.g., 2 H. 3 H, deuterium D, tritium T); carbon isotopes (such as 11 C. 13 C and 14 C); isotopes of chlorine (e.g. 37 Cl); isotopes of fluorine (e.g. 18 F); isotopes of iodine (such as 123 I and 125I); isotopes of nitrogen (e.g. 13 N and 15 N); oxygen isotopes (e.g. 15 O. 17 O and 18 O); and sulfur isotopes (e.g. 35 S).
[0085] The terms "comprises," "comprising," "having," "containing," or "involving," and other variations thereof herein, are inclusive or open-ended and do not exclude additional unrecited elements or method steps.
[0086] The term "alkyl" refers to a group obtained by removing one hydrogen atom from a straight-chain or branched hydrocarbon group, for example, "C 1-20 Alkyl", "C 1-10 Alkyl", "C 1- 6 alkyl", "C 1-4 Alkyl", "C 1-3 alkyl”, etc., specific examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, 1,2-dimethylpropyl, etc.
[0087] As used herein, the term "haloalkyl" refers to an alkyl group substituted by one or more (such as 1 to 3) the same or different halogen atoms. 1-4 "Haloalkyl" refers to C 1-4 The alkyl group is substituted by one or more halogen atoms that are the same or different, such as -CF3, -C2F5, -CHF2, -CH2F, -CH2CF3, -CH2Cl or -CH2CH2CF3.
[0088] As used herein, the term "hydroxyalkyl" refers to a group in which a hydrogen atom in an alkyl group is replaced by one or more hydroxyl groups, for example, C 1- 4-hydroxyalkyl or C 1-6 Examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, -CH(OH)CH3, and the like.
[0089] As used herein, the term "alkenyl" refers to a straight or branched aliphatic hydrocarbon group having one or more carbon-carbon double bonds. 2-6The term "alkenyl" refers to an alkenyl group having 2 to 6 carbon atoms and one, two or three carbon-carbon double bonds (e.g., ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, 4-methyl-3-pentenyl, etc.), which is optionally substituted with one or more (e.g., 1 to 3) substituents described herein.
[0090] As used herein, the term "alkynyl" refers to a straight or branched aliphatic hydrocarbon group having one or more carbon-carbon triple bonds. 2-6 The term "alkynyl" refers to an alkynyl group having 2 to 6 carbon atoms and one, two or three carbon-carbon triple bonds (e.g., ethynyl, 1-propynyl, 2-propynyl, 2-butynyl, 3-butynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, etc.), which is optionally substituted with one or more (e.g., 1 to 3) substituents described herein.
[0091] As used herein, the term "alkoxy" refers to an alkyl (as defined above) group attached to the remainder of the molecule via an oxygen atom, such as a C 1-8 Alkoxy, C 1-6 Alkoxy, C 1-4 Alkoxy or C 1-3 Alkoxy. C 1-6 Representative examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentyloxy, hexyloxy, and the like, wherein the alkoxy groups are optionally substituted with one or more (such as 1 to 3) identical or different substituents. For example, the term "haloalkoxy" refers to an alkoxy group wherein the hydrogen atoms are substituted with one or more (such as 1 to 3) identical or different halogen atoms.
[0092] As used herein, the term "cycloalkyl" refers to a saturated or unsaturated non-aromatic monocyclic or polycyclic (such as bicyclic) hydrocarbon ring group, including but not limited to monocyclic alkyl (such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, etc.) and bicyclic alkyl, including spirocyclic, annular (condensed) or bridged ring systems (i.e., spirocyclic alkyl, annular (condensed) alkyl and bridged cycloalkyl, such as bicyclo [1.1.1] pentyl, bicyclo [2.2.1] heptyl, etc.). In the present invention, cycloalkyl is optionally substituted with one or more (such as 1 to 3) identical or different substituents. The carbon atoms on the cycloalkyl are optionally substituted with oxo (oxo) groups (i.e., forming C=O). The term "C 3-8 "Cycloalkyl" refers to a cycloalkyl group having 3 to 8 ring carbon atoms, such as C3-6 Cycloalkyl, which may be a monocyclic alkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, or a bicyclic alkyl, such as C 5-8 Spiroalkyl, C 5-8 Bridged cycloalkyl, C 5-8 Condensed cycloalkyl, C 5-6 Spiroalkyl, C 5-6 Bridged cycloalkyl or C 5- 6-fused cycloalkyl. The term "aliphatic ring" refers to a saturated or unsaturated carbon ring containing 3 or more carbon atoms connected together, common aliphatic rings include cyclopropane, cyclobutane, cyclopentane, cyclohexane, etc.
[0093] As used herein, the term "heterocyclyl" or "heterocycle" refers to an aliphatic, saturated or partially unsaturated monocyclic or polycyclic (e.g., cyclic, spirocyclic or bridged) group having 2 or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14) carbon atoms and one or more (e.g., 1, 2, 3 or 4) heteroatoms, including but not limited to oxygen atoms, nitrogen atoms and sulfur atoms, wherein the carbon atoms and heteroatoms on the heterocyclyl are optionally substituted with oxo groups (e.g., forming C=O, S(=O) or S(=O)2), or are optionally substituted with one or more (e.g., 1 to 3) independently selected from halogen and C 1-3 The alkyl group is substituted with a substituent.
[0094] As used herein, the term "aryl" or "aromatic ring" refers to an all-carbon monocyclic or fused polycyclic aromatic group having a conjugated π electron system. 6-10 "Aryl" or "aromatic ring" refers to an aromatic group or aromatic ring containing 6 to 10 carbon atoms, for example, phenyl or a benzene ring, naphthyl or a naphthalene ring. The aryl group is optionally substituted by one or more (such as 1 to 3) identical or different substituents (for example, halogen, OH, CN, NO2, C 1- 6 alkyl, etc.) substituted.
[0095] As used herein, the term "heteroaryl" or "heteroaromatic ring" refers to a monocyclic or polycyclic aromatic group containing one or more identical or different heteroatoms, including monocyclic heteroaryl groups and bicyclic or polycyclic ring systems containing at least one heteroaromatic ring (an aromatic ring system containing at least one heteroatom), which can have 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, for example 5, 6, 7, 8, 9 or 10 ring atoms. The heteroatom can be oxygen, nitrogen or sulfur. The carbon atoms and heteroatoms on the heteroaryl are optionally substituted with oxo groups (for example, to form C=O, S(=O) or S(=O)2).
[0096] As used herein, the term "halo" or "halogen" group is defined to include F, Cl, Br, or I.
[0097] The term "isotopically labeled compound" means a compound that is identical in structure to a compound of the present invention except that one or more atoms are replaced by an atom having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number prevalent in nature. Examples of suitable isotopes for inclusion in the present invention include, but are not limited to, isotopes of hydrogen (e.g., 2 H. 3 H, deuterium D, tritium T); carbon isotopes (such as 11 C. 13 C and 14 C); isotopes of chlorine (e.g. 37 Cl); isotopes of fluorine (e.g. 18 F); isotopes of iodine (such as 123 I and 125 I); isotopes of nitrogen (e.g. 13 N and 15 N); oxygen isotopes (e.g. 15 O. 17 O and 18 O); and sulfur isotopes (e.g. 35 S).
[0098] The term "substituted" refers to the replacement of one or more (e.g., 1, 2, 3, 4, or 5) hydrogen atoms on a designated compound or structural fragment with a substituent, provided that the normal valence of the designated atom in the present context is not exceeded and the substitution forms a stable compound. Combinations of substituents and / or variables are permitted only if such combinations form stable compounds. For example, the substituents are each independently composed of one or more of the following structures: -O-, -S-, -NR'-, halogen, -CN, -OH, -NH2, -NO2, -CN, =O, C1-C6 alkylene, C1-C6 haloalkylene, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkylene, 3-8 membered heterocyclyl, C6-C 10 (Ethyl)aryl and 5-10 membered (Ethyl)heteroaryl, etc.
[0099] If substituents are described as being "independently selected" from a group, each substituent is selected independently of the other. Thus, each substituent may be the same as or different from another (other) substituent.
[0100] As used herein, the term "one or more" means 1 or more than 1, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10, where reasonable.
[0101] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any suitable position of the substituent.
[0102] The term "stereoisomer" refers to an isomer formed due to at least one asymmetric center. In a compound with one or more (e.g., one, two, three, or four) asymmetric centers, it can produce a racemic mixture, a single enantiomer, a diastereomeric mixture, and a separate diastereomer. Specific individual molecules can also exist as geometric isomers (cis / trans). Similarly, the compounds of the present invention can exist as mixtures of two or more structurally different forms in rapid equilibrium (commonly referred to as tautomers). Representative examples of tautomers include keto-enol tautomers, phenol-ketone tautomers, nitroso-oxime tautomers, imine-enamine tautomers, etc. For example, nitroso-oxime can exist in the following tautomeric form equilibrium in solution:
[0103] It is to be understood that the scope of this application encompasses all such isomers in any proportion (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%) or mixtures thereof.
[0104] In this article, solid lines (——), solid wedges or virtual wedge The chemical bonds of the compounds of the present invention are depicted. The use of solid lines to depict bonds to asymmetric carbon atoms is intended to indicate that all possible stereoisomers at that carbon atom are included (e.g., specific enantiomers, racemic mixtures, etc.). The use of solid or dashed wedges to depict bonds to asymmetric carbon atoms is intended to indicate that the indicated stereoisomers exist. When present in a racemic mixture, solid and dashed wedges are used to define relative stereochemistry, not absolute stereochemistry. Unless otherwise indicated, the compounds of the present invention are intended to exist as stereoisomers, including cis and trans isomers, optical isomers (e.g., R and S enantiomers), diastereomers, geometric isomers, rotational isomers, conformational isomers, atropisomers, and mixtures thereof. The compounds of the present invention may exhibit more than one type of isomerism and consist of mixtures thereof (e.g., racemic mixtures and diastereomeric pairs).
[0105] The present invention encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be single polymorphs or mixtures of more than one polymorph in any ratio.
[0106] A cocrystal refers to a drug active molecule and other physiologically acceptable acid, base, salt, or non-ionic compound molecules bound in the same crystal lattice by hydrogen bonds, π-π stacking, van der Waals forces, and other non-covalent bonds.
[0107] It should also be understood that certain compounds of the present invention may be used therapeutically in free form or, where appropriate, in the form of pharmaceutically acceptable derivatives thereof. In the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, esters, solvates, N-oxides, metabolites, or prodrugs that, upon administration to a patient in need thereof, are capable of directly or indirectly providing a compound of the present invention or a metabolite or residue thereof. Therefore, when reference is made herein to a "compound of the present invention," such various derivative forms of the compound are also intended to be encompassed.
[0108] Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof, such as hexafluorophosphate salts and meglumine salts. For a review of suitable salts, see Stahl and Wermuth, "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" (Wiley-VCH, 2002).
[0109] As used herein, the term "ester" refers to esters derived from the compounds of the general formulae herein, including physiologically hydrolyzable esters (which can be hydrolyzed under physiological conditions to release the compounds of the present invention in the form of free acid or alcohol). The compounds of the present invention themselves may also be esters.
[0110] The compounds of the present invention may exist in the form of solvates (preferably hydrates), wherein the compounds of the present invention contain a polar solvent as a structural element of the crystal lattice of the compound, in particular water, methanol or ethanol. The amount of polar solvent, in particular water, may be present in a stoichiometric or non-stoichiometric ratio.
[0111] Those skilled in the art will appreciate that, because nitrogen requires available lone pairs of electrons to be oxidized to oxides, not all nitrogen-containing heterocycles can form N-oxides. Those skilled in the art will recognize nitrogen-containing heterocycles that can form N-oxides. Those skilled in the art will also recognize that tertiary amines can form N-oxides. The synthetic method for preparing the N-oxide of heterocycles and tertiary amines is well known to those skilled in the art, including but not limited to oxidizing heterocycles and tertiary amines with peroxyacids such as Peracetic Acid and Metachloroperbenzoic Acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate and dioxirane such as dimethyldioxirane. These methods for preparing N-oxides have been extensively described and reviewed in the literature, see for example: TL Gilchrist, Comprehensive Organic Synthesis, vol. 7, pp 748-750; AR Katritzky and AJ Boulton, Eds., Academic Press; and GWH Cheeseman and ESGWerstiuk, Advances in Heterocyclic Chemistry, vol. 22, pp 390-392, AR Katritzky and AJ Boulton, Eds., Academic Press.
[0112] Also included within the scope of the present invention are metabolites of the compounds of the invention, i.e., substances formed in vivo upon administration of the compounds of the invention. Such products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis, etc. of the administered compound. Thus, the present invention includes metabolites of the compounds of the invention, including compounds produced by contacting a compound of the invention with a mammal for a period of time sufficient to produce a metabolic product thereof.
[0113] The present invention further includes within its scope prodrugs of the compounds of the present invention, which are certain derivatives of the compounds of the present invention that may themselves have little or no pharmacological activity and can be converted into compounds of the present invention having the desired activity by, for example, hydrolytic cleavage when administered to the body or thereon. Typically, such prodrugs will be functional group derivatives of the compounds that are readily converted into the desired therapeutically active compounds in vivo. Additional information on the use of prodrugs can be found in "Pro-drugs as Novel Delivery Systems", Volume 14, ACS Symposium Series (T. Higuchi and V. Stella). Prodrugs of the present invention can be prepared, for example, by replacing appropriate functional groups present in the compounds of the present invention with certain moieties known to those skilled in the art as "pro-moieties" (e.g., as described in "Design of Prodrugs", H. Bundgaard (Elsevier, 1985)).
[0114] The present invention also encompasses compounds of the present invention that contain protecting groups. During any process for preparing the compounds of the present invention, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules involved, thereby forming a chemically protected form of the compounds of the present invention. This can be achieved using conventional protecting groups, for example, those described in TW Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which references are incorporated herein by reference. Protecting groups can be removed at an appropriate subsequent stage using methods known in the art.
[0115] If a functional group or structural moiety is described as "substituted or unsubstituted" or "optionally substituted," the functional group or structural moiety may be (1) unsubstituted or (2) substituted. BRIEF DESCRIPTION OF THE DRAWINGS
[0116] Figure 1 shows the tumor inhibition effect of anti-human HER2 antibody-drug conjugate ADC on the NCI-N87 cell subcutaneous tumor-bearing mouse model.
[0117] FIG2 shows the changes in body weight of mice in each group in the human gastric cancer cell NCI-N87 CDX model.
[0118] FIG3 shows the efficacy of anti-human HER2 antibody-drug conjugate ADC in a JIMT-1 cell subcutaneous tumor-bearing mouse model.
[0119] FIG4 shows the changes in body weight of mice in each group in the human breast cancer cell JIMT-1 CDX model. DETAILED DESCRIPTION
[0120] The present invention will be further described below by describing specific embodiments, but this is not intended to limit the present invention. Those skilled in the art can make various modifications or improvements based on the teachings of the present invention without departing from the basic idea and scope of the present invention.
[0121] The sequence information of the antibodies involved in the present invention is described in the following table:
[0122] The abbreviations used in this document have the following meanings:
[0123] The structures of the compounds described in the following examples were determined by nuclear magnetic resonance ( 1 H NMR) or mass spectrometry (MS).
[0124] Nuclear magnetic resonance (1H NMR) measurements were performed using a Bruker 400 MHz NMR spectrometer; the deuterated reagent was hexadeuterated dimethyl sulfoxide (DMSO-d6); and the internal standard was tetramethylsilane (TMS).
[0125] The abbreviations used in the nuclear magnetic resonance (NMR) spectra in the examples are shown below.
[0126] s: singlet, d: doublet, t: triplet, q: quartet, m: multiplet, br: broad, J: coupling constant, Hz: hertz, DMSO-d6: deuterated dimethyl sulfoxide. δ values are expressed in ppm.
[0127] Mass spectrometry (MS) was performed using an Agilent (ESI) mass spectrometer, model Agilent 6120B.
[0128] Intermediate Example 1: Preparation of 1-(3,5-bis(2-(methylsulfonyl)pyrimidin-5-yl)phenyl)-2,5,8,11,14,17,20,23,26,29-decamethyl-1,4,7,10,13,16,19,22,25,28-decaoxo-2,5,8,11,14,17,20,23,26,29-decaazatriacontane-31-carboxylic acid (INT-1):
[0129] Step 1: Preparation of 1-(3,5-bis(2-(methylthio)pyrimidin-5-yl)phenyl)-2,5,8,11,14,17,20,23,26,29-decamethyl-1,4,7,10,13,16,19,22,25,28-decaoxo-2,5,8,11,14,17,20,23,26,29-decaazatriacontane-31-carboxylic acid (INT-1-2)
[0130] Use standard solid phase synthesis methods:
[0131] 1) Resin Preparation: 2-CTC resin (3.00 mmol, 3.70 g, 0.81 mmol / g), N-(((9H-fluoren-9-yl)methoxy)carbonyl)-N-methylglycine (3.00 mol, 933 mg, 3.00 equiv), and DIPEA (4.00 equiv) were added to dichloromethane (10.0 mL) and reacted under a nitrogen atmosphere for 2 hours. MeOH (1.0 mL) was then added to the resin under a nitrogen bubbling atmosphere over 30 minutes, and the resin was filtered to obtain the obtained product.
[0132] 2) Coupling: A solution of N-(((9H-fluoren-9-yl)methoxy)carbonyl)-N-methylglycine (5.60 g, 6.00 equiv) and HATU (6.58 g, 5.70 equiv) in DMF (10.0 mL) was added to the resin under nitrogen bubbling. DIPEA (6.00 equiv) was added dropwise, and nitrogen was bubbled at 20°C for 30 minutes. The resin was washed with DMF (30.0 mL x 5) before proceeding to the next step.
[0133] 3) Deprotection: A 20% piperidine DMF solution (30.0 mL) was added to the resin and bubbled with nitrogen at 20° C. for 30 minutes. The resin was then washed with DMF (30.0 mL) × 5.
[0134] 4) Repeat steps 2 and 3 using the amino acids numbered 2-10 in the table below.
[0135] 5) The resin was then washed with DMF (30.0 mL x 5) and MeOH (30.0 mL x 5), and then dried under vacuum.
[0136] Peptide cleavage and purification:
[0137] 1) Add cleavage solution (TFA / DCM, 1 / 100, v / v, 200.0 mL) to the flask containing the side-chain protected peptide at room temperature and stir for 3 minutes twice.
[0138] 2) After filtration, the filtrates were combined and concentrated.
[0139] 3) The crude product was purified by HPLC and freeze-dried to give the title compound (1117.1 mg, TFA salt).
[0140] Its structural characterization data are as follows:
[0141] ESI-MS (m / z): 1010.4 (M+H) + .
[0142] The purification method is as follows:
[0143] Step 2: Preparation of 1-(3,5-bis(2-(methylsulfonyl)pyrimidin-5-yl)phenyl)-2,5,8,11,14,17,20,23,26,29-decamethyl-1,4,7,10,13,16,19,22,25,28-decaoxo-2,5,8,11,14,17,20,23,26,29-decaazatriacontane-31-carboxylic acid (INT-1)
[0144] 1-(3,5-bis(2-(methylthio)pyrimidin-5-yl)phenyl)-2,5,8,11,14,17,20,23,26,29-decamethyl-1,4,7,10,13,16,19,22,25,28-decaoxo-2,5,8,11,14,17,20,23,26,29-decaazatriacontane-31-carboxylic acid (665 mg, 615.04 μmol) was added to water (7.5 mL) and acetonitrile (15 mL), and sodium periodate (1.32 g, 6.15 mmol) and ruthenium trichloride hydrate (51.03 mg, 246.02 μmol) were added, and the mixture was reacted at 25°C for 1 hour. The reaction solution was directly purified by reverse phase purification (acetonitrile / water (0.05% formic acid) = 0-25%) and freeze-dried to obtain the title compound (515 mg, 449.69 μmol).
[0145] Its structural characterization data are as follows:
[0146] ESI-MS (m / z): 1074.4 (M+H) + .
[0147] Intermediate Example 2: Preparation of 1-(3,5-bis(2-(methylsulfonyl)pyrimidin-5-yl)phenyl)-1-oxo-5,8,11,14,17,20,23,26-octaoxa-2-azanonacosane-29-oic acid (INT-2)
[0148] Step 1: Preparation of 3,5-bis(2-(methylthio)pyrimidin-5-yl)benzoic acid methyl ester (INT-2-2)
[0149] The raw materials methyl 3,5-dibromobenzoate (720 mg, 2.45 mmol), 2-methylthiopyrimidine-5-boronic acid (874 mg, 5.14 mmol), XPhosPd G3 (207 mg, 245 μmol), and K3PO4 (1.56 g, 7.35 mmol) were added to dioxane (12 mL) and water (4 mL). The reaction system was stirred at 90°C under a nitrogen atmosphere for 3 hours. The reaction was monitored by LC-MS, and the mixture was filtered through celite. Water and ethyl acetate were added to the filtrate, extracted, and concentrated to obtain a crude product, which was purified by column chromatography (EA / PE = 0-25%) to obtain 710 mg of the title compound.
[0150] Its structural characterization data are as follows:
[0151] ESI-MS (m / z): 385.1 [M+H] + .
[0152] Step 2: Preparation of 3,5-bis(2-(methylthio)pyrimidin-5-yl)benzoic acid (INT-2-3)
[0153] Methyl 3,5-bis(2-(methylthio)pyrimidin-5-yl)benzoate (650 mg, 1.69 mol) and lithium hydroxide (121 mg, 5.07 mmol) were dissolved in THF (2 mL), MeOH (2 mL), and H₂O (2 mL). The reaction was stirred at 25°C for 2 hours and monitored by LC-MS. The pH was adjusted to approximately 2 with 1N HCl, resulting in the precipitation of a large amount of solid. The filter cake was collected by filtration and dried to yield 560 mg of the title compound.
[0154] Its structural characterization data are as follows:
[0155] ESI-MS (m / z): 371.1 [M+H] + .
[0156] Step 3: Preparation of 1-(3,5-bis(2-(methylthio)pyrimidin-5-yl)phenyl)-1-oxo-5,8,11,14,17,20,23,26-octaoxa-2-azanonacosane-29-oic acid tert-butyl ester (INT-2-4)
[0157] 3,5-Bis(2-(methylthio)pyrimidin-5-yl)benzoic acid (3.00 g, 8.10 mmol) and tert-butyl 1-amino-3,6,9,12,15,18,21,24-octaoxaheptane-27-ate (4.03 g, 8.10 mmol) were added to DMF (40 mL). HOBt (3.28 g, 24.3 mmol), EDCI (4.66 g, 24.3 mmol), and DIPEA (4.19 g, 32.4 mmol, 5.64 mL) were added sequentially. The reaction system was stirred at 60°C for 2 hours. Water (100 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (60 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the title compound (4.20 g, 4.14 mmol), which was used directly in the next step without purification.
[0158] Step 4: Preparation of 1-(3,5-bis(2-(methylthio)pyrimidin-5-yl)phenyl)-1-oxo-5,8,11,14,17,20,23,26-octaoxa-2-azanonacosane-29-oic acid (INT-2-5)
[0159] Dissolve tert-butyl 1-(3,5-bis(2-(methylthio)pyrimidin-5-yl)phenyl)-1-oxo-5,8,11,14,17,20,23,26-octaoxa-2-azanonacosadecane-29-oate (3.60 g, 4.24 mmol) in dichloromethane (30 mL). Add TFA (15.3 g, 134 mmol, 10 mL). Stir the reaction at 25°C for 6 hours. Add water (60 mL) and extract with ethyl acetate (40 mL x 3). Combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate to obtain the crude product, which is purified by preparative HPLC and freeze-dried to afford the title compound (2.93 g, 3.63 mmol).
[0160] Its structural characterization data are as follows:
[0161] ESI-MS (m / z): 794.3 [M+H] + .
[0162] The purification method is as follows:
[0163] Chromatographic column: Phenomenex luna C18 (250mm*70mm*10μm)
[0164] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)
[0165] Step 5: Preparation of 1-(3,5-bis(2-(methylsulfonyl)pyrimidin-5-yl)phenyl)-1-oxo-5,8,11,14,17,20,23,26-octaoxa-2-azanonacosane-29-oic acid (INT-2)
[0166] 1-(3,5-bis(2-(methylthio)pyrimidin-5-yl)phenyl)-1-oxo-5,8,11,14,17,20,23,26-octaoxa-2-azanonaconicoside-29-oic acid (148 mg, 0.186 mmol) was added to acetonitrile (15 mL) and water (7.5 mL), and then sodium periodate (398.71 mg, 1.86 mmol) and ruthenium trichloride hydrate (15.47 mg, 74.56 μmol) were added to the reaction system. The reaction was stirred at 25°C for 30 minutes. The reaction system was extracted with water and ethyl acetate and concentrated to obtain the title compound (155 mg).
[0167] Its structural characterization data are as follows:
[0168] ESI-MS (m / z): 858.3 [M+H] + .
[0169] Intermediate Example 3: Preparation of 2-((((4-((allyloxy)carbonyl)piperidin-1-yl)sulfonyl)carbamoyl)oxy)acetic acid (INT-3)
[0170] Step 1: Preparation of allyl 1-(N-((2-(tert-butoxy)-2-oxoethoxy)carbonyl)aminosulfonyl)piperidine-4-carboxylate (INT-3-2)
[0171] Chlorosulfonyl isocyanate (2.14 g, 15.13 mmol, FR) was added to dichloromethane (50 mL) and cooled in an ice-water bath for 10 minutes. Tert-butyl 2-hydroxyacetate (2 g, 15.13 mmol, FR) was then added to the reaction system and stirred in the ice-water bath for 2 hours. Allyl piperidine-4-carboxylate hydrochloride (3.74 g, 18.16 mmol) and triethylamine (4.59 g, 45.40 mmol) were added to the reaction system. The ice-water bath was removed, and the mixture was allowed to return to room temperature and stirred for 3 hours. Water (100 mL) was added to the reaction system to quench the reaction. The mixture was extracted with ethyl acetate three times (50 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered and concentrated to obtain the crude product. The product was purified on a silica gel column (DCM / PE = 0-100%) to yield the title compound (1.87 g, 4.19 mmol).
[0172] Its structural characterization data are as follows:
[0173] 1H NMR (400MHz, DMSO) δ11.64(s,1H),6.06-5.79(m,1H),5.35-5.17(m,2H),4.61-4.48(m,4H),4.03(q,J=7.1Hz,1H),3.5 9(dt,J=12.4,3.3Hz,2H),3.04-2.88(m,2H),1.93(dd,J=13.5,3.2Hz,2H),1.59(dd,J=13.4,3.6Hz,2H),1.43(s,9H).
[0174] Step 2: Preparation of 2-((((4-((allyloxy)carbonyl)piperidin-1-yl)sulfonyl)carbamoyl)oxy)acetic acid (INT-3)
[0175] Allyl 1-(N-((2-(tert-Butoxy)-2-oxoethoxy)carbonyl)aminosulfonyl)piperidine-4-carboxylate (1.75 g, 4.31 mmol, FR) was added to a mixed solvent of trifluoroacetic acid (5 mL) and dichloromethane (10 mL) and reacted at 25°C for 2 hours. The reaction system was concentrated to dryness, diluted with ethyl acetate, and the pH was adjusted to approximately 8 with aqueous sodium bicarbonate. Impurities were removed by extraction, and the pH was adjusted to approximately 3 with 3N dilute hydrochloric acid. The mixture was extracted with ethyl acetate three times (30 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the title compound (1.4 g, 4.00 mmol).
[0176] Its structural characterization data are as follows:
[0177] ESI-MS (m / z): 351.1 [M+H] + .
[0178] Preparation Example 1: (2S,4S)-2,5,12-trihydroxy-N-(2-hydroxyethyl)-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-carboxamide (6-3)
[0179] Step 1: Preparation of (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid (6-3-2)
[0180] (8S,10S)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-7,8,9,10-tetrahydronaphthacene-5,12-dione (157 mg, 244.69 μmol) was added to methanol (3 mL) and water (2 mL), followed by sodium periodate (78.51 mg, 367.04 μmol). After addition, the mixture was stirred at room temperature in the dark. After completion of the reaction, the mixture was concentrated under reduced pressure and the solvent was removed by lyophilization to obtain the title compound (142 mg, 210.42 μmol), which was used directly in the next step without purification.
[0181] Its structural characterization data are as follows:
[0182] MSm / z(ESI):628.2[M+H] +
[0183] Step 2: Preparation of (2S,4S)-2,5,12-trihydroxy-N-(2-hydroxyethyl)-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxamide (6-3)
[0184] To DMF (2 mL) was added (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid (50 mg, 79.67 μmol), 4-dimethylaminopyridine (38.93 mg, 318.68 μmol), EDCI (30.55 mg) and 2-aminoethanol (14 mg, 229.20 μmol). After the addition was complete, the temperature was raised to 35°C / 45°C under nitrogen protection for reaction. After the reaction, the title compound (2.04 mg, 2.89 μmol) was obtained by direct purification using preparative HPLC and freeze-drying.
[0185] Its structural characterization data are as follows:
[0186] MSm / z(ESI):671.4[M+H] +
[0187] The separation and purification method is as follows
[0188] Column: Waters XBridge Prep C18 OBD (5μm*19mm*150mm)
[0189] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0190] Preparation Example 2: (2-Hydroxyethyl)(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylate (6-6)
[0191] To DMF (2 mL) was added (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid (50 mg, 79.67 μmol), potassium carbonate (28.06 mg, 203.06 μmol), and sodium iodide (12.17 mg, 81.22 μmol). The reaction was stirred at room temperature for 20 min. Finally, 2-bromoethanol (20.30 mg, 162.45 μmol) was added, and the temperature was raised to 65°C. After the reaction, the title compound (5.95 mg, 8.42 μmol) was obtained by direct purification using preparative HPLC and freeze-drying.
[0192] Its structural characterization data are as follows:
[0193] MSm / z(ESI):672.2[M+H] +
[0194] The separation and purification method is as follows
[0195] Column: Waters XBridge Prep C18 OBD (5μm*19mm*150mm)
[0196] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0197] Preparation Example 3: S-(1-amino-2-methylpropan-2-yl)(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-carbonothioate (6-7)
[0198] Step 1: Preparation of (9H-fluoren-9-yl)methyl (2-mercapto-2-methylpropyl)carbamate (6-7-2)
[0199] 1-Amino-2-methylpropane-2-thiol hydrochloride (0.5 g, 3.53 mmol) was dissolved in THF (10 mL) and water (2 mL). Sodium bicarbonate (593.01 mg, 7.06 mmol) was added, followed by 9-fluorenylmethyl-N-succinimidyl carbonate (1.13 g, 3.53 mmol). The mixture was stirred at room temperature for 2 hours. After completion of the reaction, 10 mL of water was added to the reaction solution, and the mixture was extracted with ethyl acetate three times (10 mL x 3). The mixture was washed with brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude title compound (1.12 g, 3.43 mmol), which was used directly in the next reaction without purification.
[0200] Its structural characterization data are as follows:
[0201] MS m / z(ESI):350.1[M+Na] +
[0202] Step 2: Preparation of S-(1-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpropan-2-yl)(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-carbonothioate (6-7-3)
[0203] (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid (86 mg, 137.03 μmol), DIPEA (35.42 mg, 274.06 μmol), and (9H-fluoren-9-yl)methyl (2-mercapto-2-methylpropyl) carbamate (67.30 mg, 205.55 μmol) were dissolved in DMF (4 mL). PyBOP (85.57 mg, 164.44 μmol) was added under nitrogen and stirred at room temperature for 0.5 h. Water (5.0 mL) was added to the reaction solution, which was extracted three times with ethyl acetate (5 mL x 3). The combined organic phases were washed with saturated sodium chloride solution (3 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The product was purified by silica gel column chromatography (ethyl acetate / petroleum ether = 0-90%) and concentrated again under reduced pressure to give the title compound (41 mg, 43.76 μmol).
[0204] Its structural characterization data are as follows:
[0205] MS m / z(ESI):937.3[M+H] +
[0206] Step 3: Preparation of S-(1-amino-2-methylpropan-2-yl)(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-thiocarbonate (6-7)
[0207] S-(1-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpropan-2-yl)(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carbonothioate (30 mg, 32.02 μmol) was dissolved in DMF (1.5 mL). Under nitrogen protection, a solution of piperidine (8.18 mg, 96.05 μmol) in DMF (1.5 mL) was added dropwise. After the addition, the system turned purple-red and stirred at room temperature for 40 minutes. The reaction solution was directly purified by preparative HPLC and freeze-dried to obtain the title compound (4.12 mg, 5.48 μmol).
[0208] Its structural characterization data are as follows:
[0209] MS m / z(ESI):715.3[M+H] +
[0210] 1H NMR (400MHz, DMSO) δ14.07(s,1H),13.25(s,1H),7.96-7.93(m,2H),7.69-7.66(m,1H),5.45(s,1H),5.25(t,J=4.4Hz,1H),5.02(s,1H),4.58(d,J =2.0Hz,1H),4.23(d,J=2.0Hz,1H),4.21-4.13(m,1H),4.00(s,3H),3.93 (dd,J=6.0,1.6Hz,1H),3.66(t,J=8.8Hz,1H),3.51(dd,J=7.6,3.6Hz,1H) ,3.39(dd,J=13.2,7.2Hz,2H),3.31(s,3H),3.19(dd,J=13.2,6.0Hz,1H),3.03(dd,J=45.2,18.4Hz,2H),2.73-2.58(m,2H),2.29(dd,J=14.8,5.6 Hz,1H),2.20(d,J=13.6Hz,1H),2.00(dd,J=14.4,6.8Hz,1H),1.69(s,2H ),1.45(s,1H),1.28(d,J=5.6Hz,4H),1.23(s,2H),1.21(d,J=6.4Hz,3H).
[0211] The separation and purification method is as follows:
[0212] Chromatographic column: Waters Xbridge Prep C18 OBD (5μm*19mm*150mm)
[0213] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0214] Preparation Example 4: Preparation of S-(1-hydroxy-2-methylpropan-2-yl)(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-thiocarbonate (6-8)
[0215] (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid (60 mg, 95.60 μmol), DIPEA (24.71 mg, 191.21 μmol) and 2-mercapto-2-methylpropan-1-ol (30.46 mg, 286.81 μmol) were dissolved in DMF (3 mL), PyBOP (59.70 mg, 114.72 μmol) was added, and the mixture was stirred at room temperature for 0.5 h. The reaction solution was directly purified by preparative HPLC and freeze-dried to obtain the title compound (5.74 mg, 7.22 μmol).
[0216] Its structural characterization data are as follows:
[0217] MS m / z(ESI):716.3[M+H] +
[0218] 1 H NMR (400MHz, CDCl3) δ13.88(s,1H),13.29(s,1H),8.03(d,J=7.2Hz,1H),7.78(t,J=8.0Hz,1H),7.39(d,J=8.4Hz,1H),5.50(s,1 H),5.29(s,1H),5.05(s,1H),4.73(s,1H),4.52(s,1H),4.10(d,J=12.8Hz,5H),3.95(s,2H),3.80(q,J=11.6Hz,2H),3.60(d,J= 11.2Hz,1H),3.46(d,J=4.8Hz,3H),3.44-3.36(m,1H),3.29(d,J=18.8Hz,1H),3.09(d,J=18.8Hz,1H),2.88(s,1H),2.77(s,1H) ,2.59(d,J=14.8Hz,1H),2.12(dd,J=14.8,3.6Hz,1H),2.02(s,1H),1.82-1.75(m,2H),1.48(d,J=3.6Hz,5H),1.45-1.37(m,4H).
[0219] The separation and purification method is as follows:
[0220] Chromatographic column: Waters Sunfire Prep C18 OBD (5μm*19mm*150mm)
[0221] Mobile phase A: acetonitrile; mobile phase B: water
[0222] Preparation Example 5: Preparation of (2S,4S)-2,5,12-trihydroxy-N-(2-hydroxyethyl)-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-N-methyl-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-carboxamide (6-10)
[0223] (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid (30 mg, 47.80 μmol) was dissolved in DMF (1 mL) and 2-(methylamino)ethane-1-ol (10 mg, 133.14 μmol) was added. The system turned black. DIPEA (12.36 mg, 95.60 μmol) and PyBOP (29.85 mg, 57.36 μmol) were added and the reaction was stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was directly purified by preparative HPLC and freeze-dried to obtain the title compound (7.17 mg, 9.90 μmol).
[0224] Its structural characterization data are as follows:
[0225] MS m / z(ESI):685.2[M+1] +
[0226] 1H NMR (400MHz, DMSO) δ14.06(s,1H),13.31(s,1H),7.95-7.88(m,2H),7.68-7.62(m,1H),5.71-5.69(m,1H),5.26-5.23(m,1H), 5.04-4.99(m,1H),4.84-4.80(m,1H),4.62-4.50(m,2H),4.23(d,J=2.0Hz,1H),4.10-4.02(m,1H),3.99(s,3H),3.93(d,J=6. 0Hz,1H),3.82-3.72(m,1H),3.70-3.60(m,2H),3.50(dd,J=7.6,3.6Hz,1H),3.40-3.36(m,4H),3.31(d,J=4.4Hz,6H),2.88(d ,J=17.6Hz,1H),2.79(s,1H),2.72-2.61(m,1H),2.45-2.35(m,2H),2.26-2.16(m,1H),1.69-1.64(m,1H),1.25-1.20(m,2H).
[0227] The preparation method is as follows:
[0228] Column: Waters SunFire Prep C18 OBD (5μm*19mm*150mm)
[0229] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0230] Preparation Example 6: Preparation of (2S,4S)-N-(2-aminoethyl)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-N-methyl-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxamide (6-11)
[0231] Step 1: Preparation of tert-butyl N-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)ethyl)-N-(methyl)carbamate (6-11-2)
[0232] Dissolve tert-butyl N-(2-aminoethyl)-N-(methyl)carbamate (0.5 g, 2.87 mmol) and 9-fluorenylmethyl-N-succinimidyl carbonate (967.99 mg, 2.87 mmol) in THF (5 mL). Add water (5 mL) and then sodium bicarbonate (241.07 mg, 2.87 mmol). Stir at room temperature for 2 hours. After completion, the reaction solution was diluted with 20 mL of ethyl acetate and washed twice with 10 mL of brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude title compound (1.2 g, 2.18 mmol), which was used directly in the next step without purification.
[0233] Its structural characterization data are as follows:
[0234] MS m / z(ESI):297.1[M+1-Boc] +
[0235] Step 2: Preparation of (9H-fluoren-9-yl)methyl N-(2-(methylamino)ethyl)carbamate hydrochloride (6-11-3)
[0236] To tert-butyl N-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)ethyl)-N-(methyl)carbamate (1.2 g, 3.03 mmol) was added a 4 M hydrogen chloride / dioxane solution (10 mL). The mixture was stirred at room temperature for 1 hour. After completion, the reaction solution was concentrated under reduced pressure. To the residue was added 20 mL of water, and the pH was adjusted to 4-5 with 4N HCl. The mixture was extracted with 10 mL of ethyl acetate twice. The organic phase was discarded, and the aqueous phases were combined and freeze-dried to afford the title compound (670 mg, 1.96 mmol) without further purification.
[0237] Its structural characterization data are as follows:
[0238] MS m / z(ESI):297.3[M+1] +
[0239] Step 3: Preparation of (9H-fluoren-9-yl)methyl (2-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-N-methyl-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-carboxamido)ethyl)carbamate (6-11-4)
[0240] (9H-Fluoren-9-yl)methyl N-(2-(methylamino)ethyl)carbamate hydrochloride, (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid (50 mg, 79.67 μmol) were dissolved in DMF (1 mL), and DIPEA (30.89 mg, 239.01 μmol) and PyBOP (49.75 mg, 95.60 μmol) were added, and the mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was diluted with 5 mL of water and extracted with 5 mL of ethyl acetate x 3. The combined organic phases were washed with 5 mL of saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 0-100%) and concentrated again under reduced pressure to obtain the title compound (18 mg, 19.87 μmol).
[0241] Its structural characterization data are as follows:
[0242] MS m / z(ESI):906.3[M+1] +
[0243] Step 4: Preparation of (2S,4S)-N-(2-aminoethyl)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-N-methyl-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxamide (6-11)
[0244] (9H-Fluoren-9-yl)methyl (2-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-N-methyl-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-carboxamido)ethyl)carbamate (18 mg, 19.87 μmol) was dissolved in DMF (2 mL), and piperidine (16.92 mg, 198.69 μmol) was added dropwise, and the mixture was stirred at room temperature for 5 minutes. After the reaction was completed, the reaction solution was directly purified by preparative HPLC and freeze-dried to obtain the title compound (2.61 mg, 3.74 μmol).
[0245] Its structural characterization data are as follows:
[0246] MS m / z(ESI):684.3[M+1] +
[0247] 1 H NMR (400MHz, DMSO) δ7.95-7.85(m,2H),7.68-7.60(m,1H),5.40-5.35(m,1H),5.27-5.20(m,1H),5.05-4.95( m,1H),4.58(s,1H),4.22(s,1H),4.17-4.03(m,1H),4.01-3.95(s,3H),3.92(d,J=4.0Hz,2H),3.66(t,J=12. 0Hz,2H),3.30(s,6H),3.06-2.97(m,2H),2.97-2.8(m,2H),2.80-2.73(m,1H),2.73-2.55(m,5H),2.34-2.25 (m,3H),2.25-2.20(m,1H),2.20-2.11(m,1H),2.08-1.94(m,1H),1.72-1.61(m,2H),1.25-1.19(d,J=8.0,2H)
[0248] The preparation method is as follows:
[0249] Chromatographic column: Waters Xbridge Prep C18 OBD (5μm*19mm*150mm)
[0250] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0251] Preparation Example 7: Preparation of 1-hydroxypropan-2-yl (2S, 4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S, 3R, 4aS, 9S, 9aR, 10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4', 3': 4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylate (6-12)
[0252] (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid (30.0 mg, 47.8 μmol) and 2-bromopropanol (99.7 mg, 717.03 μmol) were dissolved in DMF (2 mL), potassium carbonate (99.10 mg, 717.03 μmol) was added, and the temperature was raised to 50°C for 6 hours. The reaction solution was poured into dichloromethane (15 ml) and water (10 ml), the organic phase was separated, washed with saturated aqueous sodium chloride solution (2 ml), and concentrated to give a crude product, which was purified by preparative HPLC and freeze-dried to give the title compound (3.50 mg, 4.95 μmol).
[0253] Its structural characterization data are as follows:
[0254] MS m / z(ESI):686.2[M+H] +
[0255] 1 H NMR (400MHz, DMSO-d6): δ14.06(s,1H),13.28(s,1H),7.93(m,2H),7.70-7.64(m,1H),5.24 (m,1H),4.96(m,1H),4.82-4.76(m,1H),4.59(d,J=2.0Hz,1H),4.23(d,J=1.6Hz,1H),4.19 -4.15(m,1H),4.12(dd,J=10.4,5.2Hz,1H),3.99(s,2H),3.95-3.85(m,2H),3.7 9-3.72(m,1H),3.69-3.63(m,1H),3.51-3.48(m,1H),3.33(s,3H),3.30(s,2H), 3.17(d,J=5.2Hz,3H),3.11-3.05(m,1H),3.00-3.95(m,1H),2.65-2.61(m,1H), 2.27-2.24(m,1H),1.67-1.62(m,2H),1.22(d,J=6.4Hz,3H),1.11-1.02(m,3H).
[0256] The preparation method is as follows:
[0257] Chromatographic column: Waters Sunfire Prep C18 OBD (5μm*19mm*150mm)
[0258] Mobile phase A: acetonitrile; mobile phase B: 0.05% formic acid in water
[0259] Preparation Example 8: Preparation of (2S,4S)-2,5,12-trihydroxy-4-(((2R,4S,5S,6S)-5-hydroxy-4-((S)-2-methoxymorpholinyl)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-N-(2-hydroxyethyl)-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxamide (6-9)
[0260] (2S,4S)-2,5,12-trihydroxy-4-(((2R,4S,5S,6S)-5-hydroxy-4-((S)-2-methoxymorpholinyl)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid (13 mg, 23.82 μmol) was dissolved in DMF (2 mL). 2-Aminoethanol (3 mg), DIPEA (15 mg), and HATU (15 mg) were added and reacted at room temperature for 1 hour. The reaction solution was directly purified by preparative HPLC and freeze-dried to obtain the title compound (7.25 mg, 10.67 μmol).
[0261] Its structural characterization data are as follows:
[0262] MS m / z(ESI):673.2[M+1] +
[0263] 1H NMR (400MHz, DMSO) δ14.08(s,1H),13.26(s,1H),7.94(dd,J=11.7,5.3Hz,3H),7.71-7.64(m,1H),5.38(s,1H),5.30(s,1H ),4.98(s,1H),4.74(t,J=5.4Hz,1H),4.38(s,1H),4.09(s,1H),4.04-3.98(m,3H),3.79-3.71(m,1H),3.58(s,1H),3.49- 3.39(m,3H),3.26(s,3H),3.24-3.17(m,2H),2.99(dd,J=40.3,18.5Hz,2H),2.63(d,J=10.6Hz,1H),2.44(s,2H),2.25(dd ,J=14.3,5.3Hz,2H),2.11(d,J=13.7Hz,1H),1.83(dd,J=12.6,9.2Hz,1H),1.57(d,J=10.0Hz,1H),1.11(d,J=6.5Hz,3H).
[0264] The preparation method is as follows:
[0265] Column: Waters SunFire Prep C18 OBD (5μm*19mm*150mm)
[0266] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% formic acid)
[0267] Example 1: Preparation of perfluorophenyl 1-(N-((9S,12S,15S)-9,12,15-trimethyl-1,8,11,14,17-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-5,19-dioxa-2,7,10,13,16-pentaazaeicosanoyl)sulfamoyl)piperidine-4-carboxylate (K-9)
[0268] Step 1: Preparation of (S)-(1-(9H-fluoren-9-yl)-5-methyl-3,6-dioxo-2,9-dioxa-4,7-diazaundec-11-yl)carbamic acid benzyl ester (K-9-2)
[0269] To dichloromethane (20 mL) was added (S)-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propionamido)methyl acetate (1.53 g, 7.85 mmol), benzyl (2-hydroxyethyl)carbamate (3.60 g, 9.41 mmol), and pyridinium p-toluenesulfonate (985.73 mg, 3.92 mmol). The mixture was heated to 40°C and reacted for 20 h. The reaction solution was purified on a silica gel column (ethyl acetate / petroleum ether = 0% to 80%) and concentrated again to obtain the title compound (1.08 g, 1.98 mmol).
[0270] Its structural characterization data are as follows:
[0271] MS m / z(ESI):518.2[M+H] +
[0272] Step 2: Preparation of (S)-(2-((2-aminopropionamido)methoxy)ethyl)carbamic acid benzyl ester (K-9-3)
[0273] To DMF (8 mL) were added benzyl (S)-(1-(9H-fluoren-9-yl)-5-methyl-3,6-dioxo-2,9-dioxa-4,7-diazoundec-11-yl)carbamate (632 mg, 1.22 mmol) and diethylamine (267 mg, 3.66 mmol). The mixture was stirred at 25°C for 2 h. After completion of the reaction, the residual diethylamine and solvent were removed under reduced pressure to obtain the crude title compound (360 mg), which was used directly in the next step without purification.
[0274] Step 3: Preparation of (9H-fluoren-9-yl)methylbenzyl ((7S,10S,13S)-7,10-dimethyl-6,9,12-trioxo-3-oxa-5,8,11-triazatetradecane-1,13-diyl) dicarbamate (K-9-4)
[0275] To DMF (8 mL) were added crude benzyl (S)-(2-((2-aminopropionamido)methoxy)ethyl)carbamate (360 mg), (((9H-fluoren-9-yl)methoxy)carbonyl)-L-alanyl-L-alanine (466.14 mg, 1.22 mmol), DIPEA (787.69 mg, 6.09 mmol), and DMTMM condensing agent (718 mg, 2.44 mmol). The reaction was stirred at 25°C for 2 h. After completion of the reaction, water (40 mL) was added to the reaction solution to precipitate a solid, which was filtered and dried to obtain the crude title compound (800 mg), which was used directly in the next step without purification.
[0276] Step 4: Preparation of ((7S,10S,13S)-13-amino-7,10-dimethyl-6,9,12-trioxo-3-oxa-5,8,11-triazatetradecyl)carbamic acid benzyl ester (K-9-5)
[0277] Crude (9H-fluoren-9-yl)methylbenzyl ((7S,10S,13S)-7,10-dimethyl-6,9,12-trioxo-3-oxa-5,8,11-triazatetradecane-1,13-diyl) dicarbamate (800 mg) and diethylamine (204 mg, 2.80 mmol) were added to DMF (8 mL) and stirred at 25°C for 2 h. The reaction mixture was purified by reverse-phase column chromatography (acetonitrile / 0.05% formic acid aqueous solution = 0% to 30%) and lyophilized to obtain the title compound (394 mg, 855.56 μmol).
[0278] Its structural characterization is as follows:
[0279] MS m / z(ESI):438.2[M+H] +
[0280] Step 5: Preparation of 1-(N-((11S,14S,17S)-11,14,17-trimethyl-3,10,13,16,19-pentaoxo-1-phenyl-2,7,21-trioxa-4,9,12,15,18-pentaazadocosan-22-yl)sulfamoyl)piperidine-4-carboxylic acid allyl ester (K-9-6)
[0281] To DMF (1 mL) were added benzyl ((7S,10S,13S)-13-amino-7,10-dimethyl-6,9,12-trioxo-3-oxa-5,8,11-triazatetradecyl)carbamate (150 mg, 342.87 μmol), 2-((((4-((allyloxy)carbonyl)piperidin-1-yl)sulfonyl)carbamoyl)oxy)acetic acid (132.84 mg, 341.25 μmol), DIPEA (120.28 mg, 930.69 μmol), and HATU (153.35 mg, 403.30 μmol). The reaction was stirred at 25°C for 3 h. The reaction solution was purified by reverse-phase column chromatography (acetonitrile / 0.05% aqueous formic acid = 0% to 80%) and lyophilized to obtain the title compound (98 mg, 120.94 μmol).
[0282] Its structural characterization is as follows:
[0283] MS m / z(ESI):770.3[M+H] +
[0284] Step 6: Preparation of 1-(N-((11S,14S,17S)-11,14,17-trimethyl-3,10,13,16,19-pentaoxo-1-phenyl-2,7,21-trioxa-4,9,12,15,18-pentaazadocosan-22-yl)sulfamoyl)piperidine-4-carboxylic acid (K-9-7)
[0285] To DMF (1 mL) was added allyl 1-(N-((11S,14S,17S)-11,14,17-trimethyl-3,10,13,16,19-pentaoxo-1-phenyl-2,7,21-trioxa-4,9,12,15,18-pentaazadocosan-22-yl)sulfamoyl)piperidine-4-carboxylate (45 mg, 58.46 μmol) under nitrogen atmosphere. Tetrakistriphenylphosphine palladium (33.77 mg, 29.23 μmol) and tetrahydropyrrole (12.47 mg, 175.37 μmol) were added. After the addition was complete, the mixture was stirred at 25°C for 3 h. The reaction solution was purified by reverse phase column chromatography (acetonitrile / 0.05% formic acid aqueous solution = 0% to 60%) and lyophilized to give the title compound (35 mg, 45.56 μmol).
[0286] Its structural characterization is as follows:
[0287] MS m / z(ESI):730.3[M+H] +
[0288] Step 7: Preparation of 1-(N-((6S,9S,12S)-18-amino-6,9,12-trimethyl-4,7,10,13-tetraoxo-2,16-dioxa-5,8,11,14-tetraazaoctadecanoyl)sulfamoyl)piperidine-4-carboxylic acid (K-9-8)
[0289] To MeOH (8 mL) were added 1-(N-((11S,14S,17S)-11,14,17-trimethyl-3,10,13,16,19-pentaoxo-1-phenyl-2,7,21-trioxa-4,9,12,15,18-pentaazadocosan-22-yl)sulfamoyl)piperidine-4-carboxylic acid (35 mg, 45.56 μmol) and 10% Pd / C (80 mg). The mixture was stirred under hydrogen balloon pressure at 25°C for 6 h. After completion of the reaction, the mixture was filtered and the solvent was removed under reduced pressure to obtain the crude title compound (27 mg), which was used in the next step without purification.
[0290] Its structural characterization is as follows:
[0291] MS m / z(ESI):596.2[M+H] +
[0292] Step 8: Preparation of 1-(N-((9S,12S,15S)-9,12,15-trimethyl-1,8,11,14,17-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-5,19-dioxa-2,7,10,13,16-pentaazaeicosane-20-yl)sulfamoyl)piperidine-4-carboxylic acid (K-9-9)
[0293] To DMF (1 mL) was added 2,5-dioxopyrrolidin-1-yl (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylate (13.69 mg, 18.8 9μmol), crude 1-(N-((6S,9S,12S)-18-amino-6,9,12-trimethyl-4,7,10,13-tetraoxo-2,16-dioxa-5,8,11,14-tetraazaoctadecanoyl)sulfamoyl)piperidine-4-carboxylic acid (9 mg), and DIPEA (6 mg, 46.43μmol) were added, and the mixture was stirred at 25°C for 0.5h. The reaction solution was purified by HPLC and lyophilized to obtain the title compound (5 mg, 3.73μmol).
[0294] Its structural characterization is as follows:
[0295] MS m / z(ESI):1206.3[M+H] +
[0296] The preparation method is as follows:
[0297] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)
[0298] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0299] Step 9: Preparation of perfluorophenyl 1-(N-((9S,12S,15S)-9,12,15-trimethyl-1,8,11,14,17-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-5,19-dioxa-2,7,10,13,16-pentaazaeicosanoyl)sulfamoyl)piperidine-4-carboxylate (K-9)
[0300] To DMF (1 mL) was added 1-(N-((9S,12S,15S)-9,12,15-trimethyl-1,8,11,14,17-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxadiazol-1-yl)-1-nitropropane To the mixture were added (5 mg, 3.73 μmol), pentafluorophenol (2 mg, 11.12 μmol), and EDCI (1.07 mg, 5.56 μmol), and the mixture was stirred at 25°C for 3 h. The reaction mixture was purified by HPLC and lyophilized to afford the title compound (1.5 mg, 1.1 μmol).
[0301] Its structural characterization is as follows:
[0302] MS m / z(ESI):1372.3[M+H] +
[0303] The preparation method is as follows:
[0304] Chromatographic column: Waters XBridge Prep C18OBD (5μm*19mm*150mm)
[0305] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium formate aqueous solution)
[0306] Example 2: 1-(N-((9S,12S,15S)-9,12,15-trimethyl-1,8,11,14,17-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[ Preparation of pentafluorophenyl 4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-2,5,19-trioxa-7,10,13,16-tetraazaeicosane-20-yl)sulfamoyl)piperidine-4-carboxylate (K-10)
[0307] Step 1: Preparation of allyl 1-(N-((2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethoxy)carbonyl)sulfamoyl)piperidine-4-carboxylate (K-10-1)
[0308] 1-Hydroxypyrrolidine-2,5-dione (24.64 mg, 214.08 μmol) and 2-((((4-((allyloxy)carbonyl)piperidin-1-yl)sulfonyl)carbamoyl)oxy)acetic acid (50 mg, 142.72 μmol) were dissolved in THF (2 mL). DCC (35.34 mg, 171.26 μmol) was added and stirred at room temperature for 1 hour. After completion of the reaction, the reaction mixture was filtered, the filter cake was washed with an appropriate amount of THF, and the filtrate was concentrated under reduced pressure to obtain the crude title compound (63 mg, 140.81 μmol), which was used directly in the next step without purification.
[0309] Its structural characterization data are as follows:
[0310] MS m / z(ESI):499.1[M+Na] +
[0311] Step 2: Preparation of (2-((((4-((allyloxy)carbonyl)piperidin-1-yl)sulfonyl)carbamoyl)oxy)acetyl)-L-alanyl-L-alanine (K-10-2)
[0312] Allyl 1-(N-((2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethoxy)carbonyl)sulfamoyl)piperidine-4-carboxylate (40 mg, 89.40 μmol) and L-alanyl-L-alanine (20.05 mg, 125.16 μmol) were dissolved in DMF (1 mL). DIPEA (23.11 mg, 178.80 μmol) was added and stirred at room temperature for 2 hours. After completion of the reaction, water was added to the reaction solution, which was then acidified with 2N dilute hydrochloric acid to pH 3-4. The solution was extracted with ethyl acetate, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was further purified by silica gel column chromatography (ethyl acetate-(ethyl acetate:methanol = 1:1)) = 0-80%) and concentrated again under reduced pressure to obtain the title compound (23 mg, 46.70 μmol).
[0313] Its structural characterization data are as follows:
[0314] MS m / z(ESI):493.2[M+H] +
[0315] Step 3: Preparation of (9H-fluoren-9-yl)methyl (S)-(1-(((2-hydroxyethoxy)methyl)amino)-1-oxopropan-2-yl)carbamate (K-10-3)
[0316] Methyl (S)-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propionamido)acetate (200 mg, 523.00 μmol) was dissolved in THF (2 mL), and ethylene glycol (324.61 mg, 5.23 mmol) and p-toluenesulfonic acid (18.01 mg, 104.60 μmol) were added. The mixture was stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was diluted with 10 mL of ethyl acetate, washed with 10 mL of saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was further purified by silica gel column chromatography (petroleum ether-ethyl acetate = 0-60%) and concentrated again under reduced pressure to obtain the title compound (140 mg, 364.18 μmol).
[0317] Its structural characterization data are as follows:
[0318] MS m / z(ESI):402.3[M+H2O] +
[0319] Step 4: Preparation of (S)-1-(9H-fluoren-9-yl)-5-methyl-3,6-dioxo-2,9-dioxa-4,7-diazaundec-11-yl 4-methylbenzenesulfonate (K-10-4)
[0320] (9H-fluoren-9-yl)methyl (S)-(1-(((2-hydroxyethoxy)methyl)amino)-1-oxopropan-2-yl)carbamate (490 mg, 1.27 mmol) was dissolved in dichloromethane (5 mL). Pyridine (151.23 mg, 1.91 mmol) was added, followed by p-toluenesulfonyl chloride (291.61 mg, 1.53 mmol). The reaction mixture was stirred at room temperature for 24 hours. Pyridine (151.23 mg, 1.91 mmol) and p-toluenesulfonyl chloride (291.61 mg, 1.53 mmol) were then added. The reaction mixture was stirred at room temperature for another 4 hours, then heated to reflux for 28 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to obtain the crude product. The product was further purified by silica gel column chromatography (petroleum ether-ethyl acetate = 0-60%) and concentrated again under reduced pressure to obtain the title compound (350 mg, 649.82 μmol).
[0321] Its structural characterization data are as follows:
[0322] MS m / z(ESI):556.3[M+H2O] +
[0323] Step 5: Preparation of (S)-1-(9H-fluoren-9-yl)-5-methyl-3,6-dioxo-2,9-dioxa-4,7-diazoundecane-11-yl(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylate (K-10-5)
[0324] (S)-1-(9H-fluoren-9-yl)-5-methyl-3,6-dioxo-2,9-dioxa-4,7-diazaundec-11-yl 4-methylbenzenesulfonate (300.00 mg, 556.99 μmol) and (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro- 1H-Pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid (60 mg, 95.60 μmol) was dissolved in DMF (2 mL) and sodium bicarbonate (32.13 mg, 382.41 μmol) was added. The mixture was stirred at room temperature for 1 hour and then heated to 45°C for 24 hours. After completion of the reaction, the reaction solution was extracted with water and ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was further purified by silica gel column chromatography (petroleum ether-ethyl acetate = 10-100%) and concentrated again under reduced pressure to obtain the title compound (25 mg, 25.15 μmol).
[0325] Its structural characterization data are as follows:
[0326] MS m / z(ESI):994.4[M+H] +
[0327] Step 6: Preparation of 2-(((S)-2-aminopropionamido)methoxy)ethyl (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylate (K-10-6)
[0328] (S)-1-(9H-fluoren-9-yl)-5-methyl-3,6-dioxo-2,9-dioxa-4,7-diazaundecan-11-yl(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylate (25.00 mg, 25.15 μmol) was dissolved in DMF (2.00 mL), piperidine (16 mg, 187.91 μmol) was added, and the mixture was stirred at room temperature for 5 minutes. After the reaction was completed, the reaction solution was extracted with water and ethyl acetate, and the organic phases were combined and concentrated under reduced pressure to obtain a crude product, which was further purified by preparative HPLC and freeze-dried to obtain the title compound (4 mg, 5.18 μmol).
[0329] Its structural characterization data are as follows:
[0330] MS m / z(ESI):772.3[M+H] +
[0331] The preparation method is as follows:
[0332] Column: Waters SunFire Prep C18 OBD (5μm*19mm*150mm)
[0333] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0334] Step 7: 1-(N-((9S,12S,15S)-9,12,15-trimethyl-1,8,11,14,17-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4 Preparation of allyl ',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-2,5,19-trioxa-7,10,13,16-tetraazaeicosane-20-yl)sulfamoyl)piperidine-4-carboxylate (K-10-7)
[0335] (2-((((4-((allyloxy)carbonyl)piperidin-1-yl)sulfonyl)carbamoyl)oxy)acetyl)-L-alanyl-L-alanine (5.11 mg, 10.37 μmol) and 2-(((S)-2-aminopropionamido)methoxy)ethyl (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctanoate were added. Hydrogen-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylate (4 mg, 5.18 μmol) was dissolved in DMF (1 mL). DMTMM (4.58 mg, 15.55 μmol) and DIPEA (2.68 mg, 20.73 μmol) were added and stirred at room temperature for 1 hour. After completion of the reaction, the reaction solution was extracted with water and ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude title compound (12 mg, 1.35 μmol), which was used directly in the next reaction without purification.
[0336] Its structural characterization data are as follows:
[0337] MS m / z(ESI):1247.3[M+H] +
[0338] Step 8: Preparation of 1-(N-((9S,12S,15S)-9,12,15-trimethyl-1,8,11,14,17-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-2,5,19-trioxa-7,10,13,16-tetraazaeicosane-20-yl)sulfamoyl)piperidine-4-carboxylic acid (K-10-8)
[0339] 1-(N-((9S,12S,15S)-9,12,15-trimethyl-1,8,11,14,17-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2 ,3,4,6,11-hexahydro-tetracen-2-yl)-2,5,19-trioxa-7,10,13,16-tetraazaeicosane-20-yl)sulfamoyl)piperidine-4-carboxylic acid allyl ester (12 mg, 9.63 μmol) was dissolved in DMF (0.5 mL), tetrahydropyrrole (1.37 mg, 19.26 μmol) and tetrakistriphenylphosphine palladium (1.11 mg, 9.63e-1 μmol) were added, and the atmosphere was replaced with nitrogen three times. The reaction mixture was stirred at room temperature under nitrogen atmosphere for 2 hours. After the reaction was completed, the reaction solution was freed from the solvent using a freeze dryer, water was added to the residue, and the insoluble matter was removed by filtration. The filtrate was purified by preparative high performance liquid chromatography and freeze-dried to obtain the title compound (2 mg, 1.66 μmol).
[0340] Its structural characterization data are as follows:
[0341] MS m / z(ESI):1206.3[M+H] +
[0342] The preparation method is as follows:
[0343] Column: Waters SunFire Prep C18 OBD (5μm*19mm*150mm)
[0344] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0345] Step 9: 1-(N-((9S,12S,15S)-9,12,15-trimethyl-1,8,11,14,17-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[ Preparation of pentafluorophenyl 4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-2,5,19-trioxa-7,10,13,16-tetraazaeicosane-20-yl)sulfamoyl)piperidine-4-carboxylate (K-10)
[0346] To-(N-((9S,12S,15S)-9,12,15-trimethyl-1,8,11,14,17-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dihydro- To a solution of (1,2,3,4,6,11-hexahydronaphthacene-2-yl)-2,5,19-trioxa-7,10,13,16-tetraazaeicosane-20-yl)sulfamoyl)piperidine-4-carboxylic acid (2 mg, 1.66 μmol) was added DMF (0.5 mL) and 2,3,4,5,6-pentafluorophenol (3.05 mg, 16.58 μmol), followed by EDCI (3 mg, 15.65 μmol). The mixture was stirred at room temperature for 1 hour. After completion of the reaction, the solvent was partially removed using a lyophilizer, purified by preparative HPLC, and freeze-dried to obtain the title compound (480.00 μg, 3.15e-1 μmol).
[0347] Its structural characterization data are as follows:
[0348] MS m / z(ESI):1373.2[M+H] +
[0349] The preparation method is as follows:
[0350] Chromatographic column: Waters Xbridge Prep C18 OBD (5μm*19mm*150mm)
[0351] Mobile phase A: acetonitrile; mobile phase B: water
[0352] Example 3: Preparation of perfluorophenyl 1-(N-((7S,10S,13S)-2,7,10,13-tetramethyl-1,6,9,12,15-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-17-oxa-2,5,8,11,14-pentaazaoctadecane-18-yl)sulfamoyl)piperidine-4-carboxylate (K-11)
[0353] Step 1: Preparation of tert-butyl ((5S,8S,11S)-1-(9H-fluoren-9-yl)-5,8,11-trimethyl-3,6,9,12-tetraoxo-2-oxa-4,7,10,13-tetraazapentadecan-15-yl)(methyl)carbamate (K-11-2)
[0354] (((9H-fluoren-9-yl)methoxy)carbonyl)-L-alanyl-L-alanyl-L-alanine (1 g, 2.21 mmol) and tert-butyl (2-aminoethyl)(methyl)carbamate (384.22 mg, 2.21 mmol) were dissolved in DMF (10 mL). HATU (1.01 g, 2.65 mmol) and DIPEA (569.99 mg, 4.41 mmol) were added and stirred at room temperature for 1 hour. After completion of the reaction, 150 mL of water was added to the reaction solution, causing a large amount of solid to precipitate. After stirring for 10 minutes, the mixture was filtered, the filter cake was washed with appropriate amount of water, and the solid was collected and dehydrated in a lyophilizer to obtain the crude title compound (900 mg, 1.48 mmol).
[0355] Its structural characterization data are as follows:
[0356] MS m / z(ESI):610.3[M+H] +
[0357] Step 2: Preparation of (9H-fluoren-9-yl)methyl ((7S,10S,13S)-7,10-dimethyl-6,9,12-trioxo-2,5,8,11-tetraazatetradec-13-yl)carbamate (K-11-3)
[0358] To tert-butyl ((5S,8S,11S)-1-(9H-fluoren-9-yl)-5,8,11-trimethyl-3,6,9,12-tetraoxo-2-oxa-4,7,10,13-tetraazapentadecan-15-yl)(methyl)carbamate (350 mg, 574.04 μmol) was added 1,4-dioxane (1 mL), followed by a 4 M hydrogen chloride / dioxane solution (3 mL). The mixture was stirred at room temperature for 1 hour, during which time solids gradually precipitated. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to afford the crude hydrochloride salt of the title compound (310 mg, 567.71 μmol).
[0359] Its structural characterization data are as follows:
[0360] MS m / z(ESI):510.3[M+H] +
[0361] Step 3: Preparation of (9H-fluoren-9-yl)methyl((7S,10S,13S)-2,7,10-trimethyl-1,6,9,12-tetraoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-2,5,8,11-tetraazatetradec-13-yl)carbamate (K-11-4)
[0362] (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid (367.32 mg, 585.29 μmol) and ( 9H-fluoren-9-yl)methyl ((7S,10S,13S)-7,10-dimethyl-6,9,12-trioxo-2,5,8,11-tetraazatetradec-13-yl)carbamate (0.376 g, 585.29 μmol) was dissolved in DMF (6 mL). DIPEA (226.93 mg, 1.76 mmol) and HATU (267.05 mg, 702.34 μmol) were added and stirred at room temperature for 2 hours. After completion of the reaction, 20 mL of water was added to the reaction solution, and the mixture was extracted with 10 mL of ethyl acetate x 5. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude title compound (755 mg, 337.30 μmol).
[0363] Its structural characterization data are as follows:
[0364] MS m / z(ESI):1120.4[M+H] +
[0365] Step 4: Preparation of (2S,4S)-N-(2-((S)-2-((S)-2-((S)-2-aminopropionamido)propionamido)propionamido)ethyl)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-N-methyl-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-carboxamide (K-11-5)
[0366] (9H-fluoren-9-yl)methyl((7S,10S,13S)-2,7,10-trimethyl-1,6,9,12-tetraoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)- 6,11-Dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-2,5,8,11-tetraazatetradec-13-yl)carbamate (755 mg, 674.61 μmol) was dissolved in DMF (15 mL), and piperidine (287.20 mg, 3.37 mmol) was added dropwise. The mixture was stirred at room temperature for 0.5 hour. After completion of the reaction, the reaction solution was purified by reverse-phase silica gel column chromatography (0.05% aqueous ammonium bicarbonate-acetonitrile = 0-80%) and lyophilized to obtain the crude product. The crude product was further purified by preparative HPLC and lyophilized to obtain the title compound (80 mg, 89.19 μmol).
[0367] Its structural characterization data are as follows:
[0368] MS m / z(ESI):897.3[M+H] +
[0369] The preparation method is as follows:
[0370] Chromatographic column: Waters Xbridge Prep C18 OBD (5μm*19mm*150mm)
[0371] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0372] Step 5: Preparation of 1-(N-((7S,10S,13S)-2,7,10,13-tetramethyl-1,6,9,12,15-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-17-oxa-2,5,8,11,14-pentaazaoctadecane-18-yl)sulfamoyl)piperidine-4-carboxylic acid allyl ester (K-11-6)
[0373] 2-((((4-((allyloxy)carbonyl)piperidin-1-yl)sulfonyl)carbamoyl)oxy)acetic acid (21.09 mg, 60.21 μmol) was dissolved in DMF (2 mL), HATU (22.89 mg, 60.21 μmol) and DIPEA (16.21 mg, 125.43 μmol) were added, and the reaction was stirred at room temperature for 0.5 hour. Then, (2S,4S)-N-(2-((S)-2-((S)-2-((S)-2-aminopropionamido)propionamido)propionamido)ethyl)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-N-methyl-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-carboxamide (45 mg, 50.17 μmol) was added and the reaction was stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was extracted with water and dichloromethane, the organic phase was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residual solvent was removed by lyophilization to obtain the title compound as a crude product (60 mg, 48.81 μmol), which was used directly in the next reaction without purification.
[0374] Its structural characterization data are as follows:
[0375] MS m / z(ESI):1230.4[M+H] +
[0376] Step 6: Preparation of 1-(N-((7S,10S,13S)-2,7,10,13-tetramethyl-1,6,9,12,15-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-17-oxa-2,5,8,11,14-pentaazaoctadecane-18-yl)sulfamoyl)piperidine-4-carboxylic acid (K-11-7)
[0377] 1-(N-((7S,10S,13S)-2,7,10,13-tetramethyl-1,6,9,12,15-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4 ,6,11-hexahydronaphthacene-2-yl)-17-oxa-2,5,8,11,14-pentaazaoctadecane-18-yl)sulfamoyl)piperidine-4-carboxylic acid allyl ester (75 mg, 61.01 μmol) was dissolved in DMF (3 mL). Tetrahydropyrrole (17.36 mg, 244.05 μmol) was added, and the system instantly changed color. Then, tetrakistriphenylphosphine palladium (35.25 mg, 30.51 μmol) was added. The atmosphere was replaced with nitrogen three times, and the reaction was stirred at room temperature under nitrogen protection for 2 hours. After completion of the reaction, the reaction solution was directly purified by preparative high-performance liquid chromatography and freeze-dried to obtain the title compound (10 mg, 8.41 μmol).
[0378] Its structural characterization data are as follows:
[0379] MS m / z(ESI):1189.3[M+H] +
[0380] The preparation method is as follows:
[0381] Chromatographic column: Waters Sunfire Prep C18 OBD (5μm*19mm*150mm)
[0382] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0383] Step 7: Preparation of perfluorophenyl 1-(N-((7S,10S,13S)-2,7,10,13-tetramethyl-1,6,9,12,15-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-yl)-17-oxa-2,5,8,11,14-pentaazaoctadecane-18-yl)sulfamoyl)piperidine-4-carboxylate (K-11)
[0384] To 1-(N-((7S,10S,13S)-2,7,10,13-tetramethyl-1,6,9,12,15-pentaoxo-1-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1, To a solution of (10.00 mg, 8.41 μmol) (2,3,4,6,11-hexahydronaphthacene-2-yl)-17-oxa-2,5,8,11,14-pentaazaoctadecane-18-yl ...sulfamoyl)pi
[0385] Its structural characterization data are as follows:
[0386] MS m / z(ESI):1355.3[M+H] +
[0387] The preparation method is as follows:
[0388] Chromatographic column: Waters Xbridge Prep C18 OBD (5μm*19mm*150mm)
[0389] Mobile phase A: acetonitrile; mobile phase B: water
[0390] Example 4: S-((31S,34S,37S)-1-(3,5-bis(2-(methylsulfonyl)pyrimidin-5-yl)phenyl)-31,34,37,41-tetramethyl-1,29,32,35,38-pentaoxo-5,8,11,14,17,20,23,26-octaoxa-2,30,33,36,39-pentaazatetradodecane-41-yl)(2S,4S Preparation of 2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4':3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-thiocarbonate (K-17)
[0391] Step 1: Preparation of 2,5-dioxopyrrolidin-1-yl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-alanine-L-alanine (K-17-2)
[0392] Dissolve (((9H-fluoren-9-yl)methoxy)carbonyl)-L-alanine-L-alanine (1 g, 2.62 mmol) in dichloromethane (10 mL). Add N-hydroxysuccinimide (300.95 mg, 2.62 mmol) and EDCI (551.43 mg, 2.88 mmol). Stir at room temperature for 2 hours. After completion, the reaction solution was washed twice with 10 mL of saturated brine. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude title compound (1.29 g, 2.42 mmol), which was used directly in the next step without purification.
[0393] Its structural characterization data are as follows:
[0394] MS m / z(ESI):497.3[M+H2O+H] +
[0395] Step 2: Preparation of (((9H-fluoren-9-yl)methoxy)carbonyl)-L-alanine-L-alanine-L-alanine (K-17-3)
[0396] 2,5-Dioxopyrrolidin-1-yl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-alanine-L-alanine (1.19 g, 2.23 mmol) and L-alanine (199.00 mg, 2.23 mmol) were dissolved in tetrahydrofuran (10 mL) and water (5 mL). Sodium bicarbonate (375.29 mg, 4.47 mmol) was added and stirred at room temperature for 1 hour. After completion of the reaction, 20 mL of water was added to the reaction solution, and the pH was adjusted to 4-5 with 2N HCl. A large amount of white flocculent material precipitated. The mixture was extracted with 20 mL of ethyl acetate x 4. The organic phase was washed with 10 mL of saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude title compound (1.23 g, 2.03 mmol), which was used directly in the next step without purification.
[0397] Its structural characterization data are as follows:
[0398] MS m / z(ESI):454.1[M+H] +
[0399] Step 3: Preparation of 2,5-dioxopyrrolidin-1-yl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-alanine-L-alanine-L-alanine (K-17-4)
[0400] (((9H-fluoren-9-yl)methoxy)carbonyl)-L-alanine-L-alanine-L-alanine (400 mg, 882.05 μmol) and N-hydroxysuccinimide (152.27 mg, 1.32 mmol) were dissolved in THF (4 mL) and DMF (2 mL). EDCI (253.64 mg, 1.32 mmol) was added and stirred at room temperature for 2 hours. After completion of the reaction, the reaction solution was diluted with 100 mL of ethyl acetate and then washed directly with 20 mL of saturated brine. The mixture was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude title compound (400 mg, 726.53 μmol), which was used directly in the next step without purification.
[0401] Its structural characterization data are as follows:
[0402] MS m / z(ESI):568.3[M+H2O+H] +
[0403] Step 4: Preparation of (9H-fluoren-9-yl)methyl ((S)-1-((S)-1-((S)-1-((2-mercapto-2-methylpropyl)amino)-1-oxopropyl-2-yl)amino)-1-oxopropyl-2-yl)carbamate (K-17-5)
[0404] 2,5-Dioxopyrrolidin-1-yl(((9H-fluoren-9-yl)methoxy)carbonyl)-L-alanine-L-alanine-L-alanine (200 mg, 363.27 μmol) was dissolved in THF (3 mL) and water (1 mL). 1-Amino-2-methylpropane-2-thiol (38.22 mg, 363.27 μmol) and sodium bicarbonate (61.03 mg, 726.53 μmol) were added. The mixture was stirred at room temperature under nitrogen for 2 hours. After completion, the reaction mixture was added with 5 mL of water and extracted with 5 mL of ethyl acetate three times. The organic phase was washed with 5 mL of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10-100%, methanol / dichloromethane = 5-10% as a final step) and concentrated under reduced pressure to obtain the title compound (93 mg, 172.01 μmol).
[0405] Its structural characterization data are as follows:
[0406] MS m / z(ESI):541.3[M+H] +
[0407] Step 5: Preparation of S-((5S,8S,11S)-1-(9H-fluoren-9-yl)-5,8,11,15-tetramethyl-3,6,9,12-tetraoxo-2-oxa-4,7,10,13-tetraazahexadecane-15-yl)(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid thioate (K-17-6)
[0408] (2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid (50 mg, 79.67 μmol) and (9H-fluoren-9-yl)methyl((S) 1-((S)-1-((S)-1-((2-mercapto-2-methylpropyl)amino)-1-oxopropyl-2-yl)amino)-1-oxopropyl-2-yl)carbamate (43.08 mg, 79.67 μmol) was dissolved in DMF (2 mL), and DIPEA (30.89 mg, 239.01 μmol) was added. PyBOP (49.75 mg, 95.60 μmol) was then added under nitrogen. After complete addition, the mixture was stirred at 25°C under a nitrogen atmosphere for 3 hours. After completion of the reaction, 10 mL of water was added to the reaction solution, followed by extraction with 10 mL of ethyl acetate x 3. The organic phase was washed with 10 mL of brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude title compound (200 mg, 78.24 μmol), which was used directly in the next step without purification.
[0409] Its structural characterization data are as follows:
[0410] MS m / z(ESI):1151.3[M+H] +
[0411] Step 6: Preparation of S-(1-((S)-2-((S)-2-((S)-2-aminopropionamido)propionamido)propionamido)-2-methylpropan-2-yl)(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylic acid thioate (K-17-7)
[0412] S-((5S,8S,11S)-1-(9H-fluoren-9-yl)-5,8,11,15-tetramethyl-3,6,9,12-tetraoxo-2-oxa-4,7,10,13-tetraazahexadec-15-yl)(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1- Methyl octahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylate (200 mg, 86.94 μmol) was dissolved in DMF (4 mL). Piperidine (60 mg, 704.66 μmol) was added and stirred at room temperature for 10 minutes. After completion of the reaction, the reaction solution was directly purified by preparative HPLC and freeze-dried to obtain the title compound (15 mg, 16.16 μmol).
[0413] Its structural characterization data are as follows:
[0414] MS m / z(ESI):928.3[M+H] +
[0415] The preparation method is as follows:
[0416] Chromatographic column: Waters Xbridge Prep C18 OBD (5μm*19mm*150mm)
[0417] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0418] Step 7: S-((31S,34S,37S)-1-(3,5-bis(2-(methylsulfonyl)pyrimidin-5-yl)phenyl)-31,34,37,41-tetramethyl-1,29,32,35,38-pentaoxo-5,8,11,14,17,20,23,26-octaoxa-2,30,33,36,39-pentaazatetradecane-41-yl)(2S,4S Preparation of 2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4':3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-2-thiocarbonate (K-17)
[0419] 1-(3,5-bis(2-(methylsulfonyl)pyrimidin-5-yl)phenyl)-1-oxo-5,8,11,14,17,20,23,26-octaoxa-2-azanonacosanetaconic acid-29-carboxylic acid (4.62 mg, 5.39 μmol) and S-(1-((S)-2-((S)-2-((S)-2-aminopropionamido)propionamido)propionamido)-2-methylpropan-2-yl)(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S, (9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylate (5 mg, 5.39 μmol) was dissolved in DMF (0.5 mL). DIPEA (2.09 mg, 16.16 μmol) was added dropwise, followed by HATU (2.46 mg, 6.47 μmol). The mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction solution was directly purified by preparative HPLC and freeze-dried to obtain the title compound (4 mg, 2.15 μmol).
[0420] Its structural characterization data are as follows:
[0421] MS m / z(ESI):1769.4[M+H] +
[0422] The preparation method is as follows:
[0423] Column: Waters SunFire Prep C18 OBD (5μm*19mm*150mm)
[0424] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0425] Example 5: S-((33S,36S,39S)-1-(3,5-bis(2-(methylsulfonyl)pyrimidin-5-yl)phenyl)-2,5,8,11,14,17,20,23,26,29,33,36,39,43-tetradecyl-1,4,7,10,13,16,19,22,25,28,31,34,37,40-tetradecanoyl-2,5,8,11,14,17,20,23,26,29,32,35, Preparation of 38,41-tetradecane-43-yl)(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carbothioate (K-18)
[0426] 1-(3,5-bis(2-(methylsulfonyl)pyrimidin-5-yl)phenyl)-2,5,8,11,14,17,20,23,26,29-decamethyl-1,4,7,10,13,16,19,22,25,28-decaoxo-2,5,8,11,14,17,20,23,26,29-decaazatriacontane-31-carboxylic acid (6.17 mg, 5.39 μmol) and S-(1-((S)-2-((S)-2-aminopropionamido)propionamido)propionamido)-2-methylpropan-2-yl)(2S,4S)-2,5,12- Trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacene-2-carboxylate (5 mg, 5.39 μmol) was dissolved in DMF (0.5 mL). DIPEA (2.09 mg, 16.16 μmol) was added dropwise, followed by HATU (2.46 mg, 6.47 μmol). The mixture was stirred at room temperature for 3 hours. After completion of the reaction, the reaction solution was directly purified by preparative HPLC and freeze-dried to obtain the title compound (6.48 mg, 3.12 μmol).
[0427] Its structural characterization data are as follows:
[0428] MS m / z(ESI):1036.6[(M+H2O) / 2] + ,691.5[(M+H2O) / 3] +
[0429] The preparation method is as follows:
[0430] Chromatographic column: Waters Xbridge Prep C18 OBD (5μm*19mm*150mm)
[0431] Mobile phase A: acetonitrile; Mobile phase B: water (0.05% ammonium bicarbonate)
[0432] 2. Antibody Preparation and Binding Activity Assay
[0433] 1. Antibody acquisition and purification
[0434] Based on the amino acid sequences of trastuzumab (IMGT / mAb-DB ID: 97) and pertuzumab (IMGT / mAb-DB ID: 80) in the IMGT database, codon optimization was performed and the encoding gene was synthesized. This gene was then constructed into an expression vector, transfected into CHO cells, and pressure-selected to construct a stable expressing cell line. The supernatant was collected after expression and purified using a Protein A affinity medium to obtain the corresponding antibody.
[0435] 3. Conjugation of Compounds Containing Cellular Bioactive Molecules and Linkers to Antibodies
[0436] The antibodies Trastuzumab and Pertuzumab involved in the antibody-drug conjugates prepared in the following examples are Trastuzumab and Pertuzumab described in the second part above.
[0437] The conjugate preparation of the antibody drug conjugate sample is as follows:
[0438] 1. Preparation of Trastuzumab-K-17
[0439] 0.3086 mL of trastuzumab antibody (16.2 mg / mL) was diluted with 15.43 uL of 20 mM PB + 0.1 M EDTA (pH 7.60), then the pH was adjusted to 8.0 with 1 M Na2HPO4 solution. 10 mM TCEP (tris(2-carboxyethyl)phosphine (18.95 uL, pH 7.60) solution was added and mixed, and the mixture was allowed to stand at room temperature for 1.5 hours. K-17 (17.4 uL, 10 mM, 5 times the equivalent of the antibody) dissolved in dimethyl sulfoxide was then added and mixed, and the mixture was allowed to stand at room temperature for 18 hours. After completion, the buffer was exchanged with a 20 mM histidine buffer solution at pH 6.0 using a NAP-5 gel column (Cytiva) to obtain the antibody-drug conjugate (i.e., trastuzumab-K-17). The DAR value determined by mass spectrometry was 4.28.
[0440] Table 1: Measured molecular weight and DAR calculation of Trastuzumab-K-17
[0441] 2. Preparation of Trastuzumab-K-18
[0442] 1.234 mL of trastuzumab antibody (16.2 mg / mL) was diluted with 61.73 uL of 20 mM PB + 0.1 M EDTA (pH 7.60), then the pH was adjusted to 8.0 with 1 M Na2HPO4 solution. 10 mM TCEP (tris(2-carboxyethyl)phosphine) solution (75.8 uL, pH 7.60) was added and mixed, and the mixture was allowed to stand at room temperature for 1.5 hours. K-18 solution dissolved in dimethyl sulfoxide (62.64 uL, 10 mM, 4.5 times the equivalent of the antibody) was then added and mixed, and the mixture was allowed to stand at room temperature for 18 hours. After completion, the buffer was exchanged with a 20 mM histidine buffer solution at pH 6.0 using a NAP-5 gel column (Cytiva) to obtain the antibody-drug conjugate (i.e., trastuzumab-K-18). The DAR value determined by mass spectrometry was 4.44.
[0443] Table 2: Trastuzumab-K-18 Measured Molecular Weight and Calculated DAR
[0444] IV. Detecting the inhibitory effect of compounds on tumor cell proliferation
[0445] 1. Inhibitory effect of the compound on NCI-N87 cell proliferation
[0446] (1) Cell plating: First, culture the tumor cells NCI-N87 in the corresponding culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to the appropriate concentration for plating. The tumor cell sources are shown in Table 3.
[0447] Table 3. Tumor cell origin
[0448] Co-incubation of the compound of the present invention and tumor cells: After the cells adhere to the wall, the culture medium in the cells is removed, and the diluted bioactive molecule (the compound of the present invention) is added to the above plate wells and incubated for 72 hours.
[0449] In vitro cell viability assay: After incubation, add 50 μL of Cell Counting-Lite™ 2.0 reagent (Vazyme / Novozyme) to each well, shake and mix in the dark. After 10 minutes of reaction, assay can be performed using a microplate reader (Manufacturer: BMG, Model: PHERAStar-FS). Background RLU values are calculated using Cell Counting-Lite™ reagents for cell-free medium, and vehicle RLU values are calculated using Cell Counting-Lite™ reagents for cell-containing medium. Cell inhibition rate = (1 - (sample RLU - background RLU) / (vehicle RLU - background RLU)) × 100%. The half-maximal inhibitory concentration (IC50) of the compound was calculated using a four-parameter curve fit. RLU (relative light unit) is the relative light unit. The assay results are shown in Tables 4-1, 4-2, 4-3, and 4-4.
[0450] (2) Data results
[0451] Table 4-1. Inhibitory activity of compounds on NCI-N87 cell proliferation
[0452] Table 4-2. Inhibitory activity of compounds on NCI-N87 cell proliferation
[0453] Table 4-3. Inhibitory activity of compounds on NCI-N87 cell proliferation
[0454] Table 4-4. Inhibitory activity of compounds on NCI-N87 cell proliferation
[0455] The test results show that the compounds of the present invention in Tables 4-1, 4-4, 4-3 and 4-4 have a significant inhibitory effect on the proliferation of NCI-N87 human gastric cancer cells.
[0456] 2. Inhibitory effect of compounds on HT29 cell proliferation
[0457] (1) Cell plating: First, culture HT29 tumor cells in the corresponding culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to the appropriate concentration for plating. The sources of tumor cells are shown in Table 5.
[0458] Table 5. Tumor cell origin
[0459] Co-incubation of the compound of the present invention and tumor cells: After the cells adhere to the wall, the culture medium in the cells is removed, and the diluted bioactive molecule (the compound of the present invention) is added to the above plate wells and incubated for 72 hours.
[0460] In vitro cell viability assay: After incubation, add 50 μL of Cell Counting-Lite™ 2.0 reagent (Vazyme / Novozyme) to each well, shake and mix thoroughly in the dark. After 10 minutes of reaction, assay can be performed using a microplate reader (Manufacturer: BMG, Model: PHERAStar-FS). Background RLU values are calculated using Cell Counting-Lite™ culture medium without cells, and vehicle RLU values are calculated using Cell Counting-Lite™ culture medium with cells. Cell inhibition rate = (1 - (sample RLU - background RLU) / (vehicle RLU - background RLU)) × 100%. The half-maximal inhibitory concentration (IC50) of the compound was calculated using a four-parameter curve fit. RLU (relative light unit): relative light unit. The assay results are shown in Tables 6-1, 6-2, 6-3, and 6-4.
[0461] (2) Data results
[0462] Table 6-1. Inhibitory activity of compounds on HT29 cell proliferation
[0463] Table 6-2. Inhibitory activity of compounds on HT29 cell proliferation
[0464] Table 6-3. Inhibitory activity of compounds on HT29 cell proliferation
[0465] Table 6-4. Inhibitory activity of compounds on HT29 cell proliferation
[0466] The test results show that the compounds of the present invention in Tables 6-1, 6-2, 6-3 and 6-4 have a strong proliferation inhibitory effect on the proliferation of HT29 colon cancer cells.
[0467] 3. Inhibitory effect of the compounds on HCC1806 cell proliferation
[0468] (1) Cell plating: First, culture HCC1806 tumor cells in the corresponding culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to the appropriate concentration for plating. The tumor cell sources are shown in Table 7.
[0469] Table 7. Tumor cell sources
[0470] Co-incubation of the compound of the present invention and tumor cells: After the cells adhere to the wall, the culture medium in the cells is removed, and the diluted bioactive molecule (the compound of the present invention) is added to the above plate wells and incubated for 72 hours.
[0471] In vitro cell viability assay: After incubation, add 50 μL of Cell Counting-Lite™ 2.0 reagent (Vazyme / Novozyme) to each well, shake and mix in the dark. After 10 minutes of reaction, assays can be performed using a microplate reader (Manufacturer: BMG, Model: PHERAStar-FS). Background RLU values were calculated using Cell Counting-Lite™ reagents for cell-free medium, and vehicle RLU values were calculated using Cell Counting-Lite™ reagents for cell-containing medium. Cell inhibition rate = (1 - (sample RLU - background RLU) / (vehicle RLU - background RLU)) × 100%. The half-maximal inhibitory concentration (IC50) of the compound was calculated using a four-parameter curve fit. RLU (relative light unit): relative light unit. The assay results are shown in Table 8.
[0472] (2) Data results
[0473] Table 8. Inhibitory activity of compounds on HCC1806 cell proliferation
[0474] The test results show that the compounds of the present invention in Table 8 have a significant inhibitory effect on the proliferation of HCC1806 human breast squamous carcinoma cells.
[0475] 4. Inhibitory effect of compounds on SK-OV-3 cell proliferation
[0476] (1) Cell plating: First, culture SKOV-3 tumor cells in the appropriate culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to an appropriate concentration for plating. The sources of tumor cells are shown in Table 9.
[0477] Table 9. Tumor cell sources
[0478] Co-incubation of the compound of the present invention and tumor cells: After the cells adhere to the wall, the culture medium in the cells is removed, and the diluted bioactive molecule (the compound of the present invention) is added to the above plate wells and incubated for 72 hours.
[0479] In vitro cell viability assay: After incubation, add 50 μL of Cell Counting-Lite™ 2.0 reagent (Vazyme / Novozyme) to each well, shake and mix in the dark. After 10 minutes of reaction, assays can be performed using a microplate reader (Manufacturer: BMG, Model: PHERAStar-FS). Background RLU values were calculated using Cell Counting-Lite™ for cell-free medium, and vehicle RLU values were calculated using Cell Counting-Lite™ for cell-containing medium. Cell inhibition rate = (1 - (sample RLU - background RLU) / (vehicle RLU - background RLU)) × 100%. The half-maximal inhibitory concentration (IC50) of the compound was calculated using a four-parameter curve fit. RLU (relative light unit): relative light unit. The assay results are shown in Table 10.
[0480] (2) Data results
[0481] Table 10. Inhibitory activity of compounds on SK-OV-3 cell proliferation
[0482] The test results show that the compounds of the present invention in Table 10 have a significant inhibitory effect on the proliferation of SK-OV-3 human ovarian cancer cells.
[0483] 5. Inhibitory effect of compounds on NCI-H358 cell proliferation
[0484] (1) Cell plating: First, culture the tumor cells NCI-H358 in the corresponding culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to the appropriate concentration for plating. The tumor cell sources are shown in Table 11.
[0485] Table 11. Tumor cell sources
[0486] Co-incubation of the compound of the present invention and tumor cells: After the cells adhere to the wall, the culture medium in the cells is removed, and the diluted bioactive molecule (the compound of the present invention) is added to the above plate wells and incubated for 72 hours.
[0487] In vitro cell viability assay: After incubation, add 50 μL of Cell Counting-Lite™ 2.0 reagent (Vazyme / Novozyme) to each well, shake and mix in the dark. After 10 minutes of reaction, assays can be performed using a microplate reader (Manufacturer: BMG, Model: PHERAStar-FS). Background RLU values were calculated using Cell Counting-Lite™ for medium without cells, and vehicle RLU values were calculated using Cell Counting-Lite™ for medium with cells. Cell inhibition rate = (1 - (sample RLU - background RLU) / (vehicle RLU - background RLU)) × 100%. The half-maximal inhibitory concentration (IC50) of the compound was calculated using a four-parameter curve fit. RLU (relative light unit): relative light unit. The assay results are shown in Table 12.
[0488] (2) Data results
[0489] Table 12. Inhibitory activity of compounds on NCI-H358 cell proliferation
[0490] The test results show that the compounds of the present invention in Table 12 have a significant inhibitory effect on the proliferation of NCI-H358 human non-small cell lung cancer cells.
[0491] 6. Inhibitory effect of compounds on KPL-4 cell proliferation
[0492] (1) Cell plating: First, culture KPL-4 tumor cells in the appropriate culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to an appropriate concentration for plating. The sources of tumor cells are shown in Table 13.
[0493] Table 13. Tumor cell sources
[0494] Co-incubation of the compound of the present invention and tumor cells: After the cells adhere to the wall, the culture medium in the cells is removed, and the diluted bioactive molecule (the compound of the present invention) is added to the above plate wells and incubated for 72 hours.
[0495] In vitro cell viability assay: After incubation, add 50 μL of Cell Counting-Lite™ 2.0 reagent (Vazyme / Novozyme) to each well, shake and mix in the dark. After 10 minutes of reaction, assays can be performed using a microplate reader (Manufacturer: BMG, Model: PHERAStar-FS). Background RLU values were calculated using Cell Counting-Lite™ for cell-free medium, and vehicle RLU values were calculated using Cell Counting-Lite™ for cell-containing medium. Cell inhibition rate = (1 - (sample RLU - background RLU) / (vehicle RLU - background RLU)) × 100%. The half-maximal inhibitory concentration (IC50) of the compound was calculated using a four-parameter curve fit. RLU (relative light unit): relative light unit. The assay results are shown in Table 14.
[0496] (2) Data results
[0497] Table 14. Inhibitory activity of compounds on KPL-4 cell proliferation
[0498] The test results show that the compounds of the present invention in Table 14 have a significant inhibitory effect on the proliferation of KPL-4 human breast cancer cells.
[0499] 7. Inhibitory effect of compounds on HCC827 cell proliferation
[0500] (1) Cell plating: First, culture HCC827 tumor cells in the appropriate culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to an appropriate concentration for plating. The sources of tumor cells are shown in Table 15.
[0501] Table 15. Tumor cell sources
[0502] Co-incubation of the compound of the present invention and tumor cells: After the cells adhere to the wall, the culture medium in the cells is removed, and the diluted bioactive molecule (the compound of the present invention) is added to the above plate wells and incubated for 72 hours.
[0503] In vitro cell viability assay: After incubation, add 50 μL of Cell Counting-Lite™ 2.0 reagent (Vazyme / Novozyme) to each well, shake and mix in the dark. After 10 minutes of reaction, assay can be performed using a microplate reader (Manufacturer: BMG, Model: PHERAStar-FS). Background RLU values were calculated using Cell Counting-Lite™ for cell-free medium, and vehicle RLU values were calculated using Cell Counting-Lite™ for cell-containing medium. Cell inhibition rate = (1 - (sample RLU - background RLU) / (vehicle RLU - background RLU)) × 100%. The half-maximal inhibitory concentration (IC50) of the compound was calculated using a four-parameter curve fit. RLU (relative light unit): relative light unit. The assay results are shown in Table 16.
[0504] (2) Data results
[0505] Table 16. Antiproliferation activity of compounds on HCC827 cells
[0506] The test results show that the compounds of the present invention in Table 16 have an inhibitory effect on the proliferation of HCC827 human non-small cell lung cancer cells.
[0507] 8. Inhibitory effect of compounds on HCC1954 cell proliferation
[0508] (1) Cell plating: First, culture HCC1954 tumor cells in the appropriate culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to an appropriate concentration for plating. The sources of tumor cells are shown in Table 17.
[0509] Table 17. Tumor cell sources
[0510] Co-incubation of the compound of the present invention and tumor cells: After the cells adhere to the wall, the culture medium in the cells is removed, and the diluted bioactive molecule (the compound of the present invention) is added to the above plate wells and incubated for 72 hours.
[0511] In vitro cell viability assay: After incubation, add 50 μL of Cell Counting-Lite™ 2.0 reagent (Vazyme / Novozyme) to each well, shake and mix in the dark. After 10 minutes of reaction, assay can be performed using a microplate reader (Manufacturer: BMG, Model: PHERAStar-FS). Background RLU values were calculated using Cell Counting-Lite™ for medium without cells, and vehicle RLU values were calculated using Cell Counting-Lite™ for medium with cells. Cell inhibition rate = (1 - (sample RLU - background RLU) / (vehicle RLU - background RLU)) × 100%. The half-maximal inhibitory concentration (IC50) of the compound was calculated using a four-parameter curve fit. RLU (relative light unit): relative light unit. The assay results are shown in Table 18.
[0512] (2) Data results
[0513] Table 18. Proliferation inhibition activity of compounds on HCC1954 cells
[0514] The test results show that the compounds of the present invention in Table 18 have an inhibitory effect on the proliferation of HCC1954 human non-small cell lung cancer cells.
[0515] 9. Inhibitory effect of compounds on NCI-H1975 cell proliferation
[0516] (1) Cell plating: First, culture the tumor cells NCI-H1975 in the corresponding culture medium, digest the cells with trypsin, centrifuge, resuspend the cells, count the cells, and adjust the cells to the appropriate concentration for plating. The tumor cell sources are shown in Table 19.
[0517] Table 19. Tumor cell sources
[0518] Co-incubation of the compound of the present invention and tumor cells: After the cells adhere to the wall, the culture medium in the cells is removed, and the diluted bioactive molecule (the compound of the present invention) is added to the above plate wells and incubated for 72 hours.
[0519] In vitro cell viability assay: After incubation, add 50 μL of Cell Counting-Lite™ 2.0 reagent (Vazyme / Novozyme) to each well, shake and mix in the dark. After 10 minutes of reaction, assays can be performed using a microplate reader (Manufacturer: BMG, Model: PHERAStar-FS). Background RLU values were calculated using Cell Counting-Lite™ for medium without cells, and vehicle RLU values were calculated using Cell Counting-Lite™ for medium with cells. Cell inhibition rate = (1 - (sample RLU - background RLU) / (vehicle RLU - background RLU)) × 100%. The half-maximal inhibitory concentration (IC50) of the compound was calculated using a four-parameter curve fit. RLU (relative light unit): relative light unit. The assay results are shown in Table 20.
[0520] (2) Data results
[0521] Table 20. Antiproliferation activity of compounds on NCI-H1975 cells
[0522] The test results show that the compounds of the present invention in Table 20 have an inhibitory effect on the proliferation of NCI-H1975 human non-small cell lung cancer cells.
[0523] The following are the structural formulas of reference compounds 1 to 3:
[0524] 5. Evaluation of the Antibody-Drug Conjugate's Inhibitory Effect on Tumor Growth in a Mouse Subcutaneous Xenograft Tumor Model
[0525] The preparation containing the ADC of the present invention was administered via tail vein injection to a CDX mouse model subcutaneously transplanted with human gastric cancer cells NCI-N87. The tumor volume and animal body weight changes were measured twice a week, and the tumor inhibition efficacy of the ADC of the present invention on tumor-bearing mice was calculated.
[0526] Test drug
[0527] Drug name, source, and preparation method: Take an appropriate amount of the ADC of the present invention, dilute the stock solution with 0.9% NaCl injection to a dosing solution at a dosage of 1 mg / kg, and use 0.9% NaCl injection as a vehicle control.
[0528] Experimental animals and cell lines
[0529] Balb / c Nude mice (Chengdu Yaokang Biotechnology Co., Ltd.)
[0530] Human gastric cancer cells NCI-N87 (ATCC)
[0531] Experimental grouping and evaluation methods
[0532] The average tumor volume was about 150 mm. 3 Tumor-bearing mice were randomly divided into groups (the number of groups was determined based on the sample size). The groups were administered 0.9% NaCl injection (hereinafter referred to as vehicle control) and the ADC of the present invention. The dosing frequency was as described in the specific examples. The administration method was tail vein injection, and the administration volume was 10 ml / kg. Tumor diameter was measured twice weekly with a vernier caliper, and tumor volume was calculated using the following formula: V = 0.5a × b 2 , where a and b represent the long and short diameters of the tumor, respectively. Animal mortality was recorded daily.
[0533] The tumor growth inhibition rate (TGI) was calculated using the following formula to evaluate the tumor inhibition efficacy of the ADC of the present invention:
[0534] V T末 >V T0 ,TGI(%)=[1-(V T末 -V T0 ) / (V C末 -V C0 )]*100% or V T末 ≤V T0 ,TGI(%)=[1-(V T末 -VT0) /
[0535] VT0]*100%.
[0536] Where V T末 : Mean tumor volume of treatment group at the end of the experiment
[0537] V T0 : Mean tumor volume at the start of drug administration in the treatment group
[0538] V C末 : Mean tumor volume of negative control group at the end of the experiment
[0539] V C0 : Mean tumor volume of negative control group at the beginning of drug administration
[0540] The following formula was used to calculate the tumor relative proliferation rate T / C (%), which was used to evaluate the tumor inhibition efficacy of the ADC of the present invention:
[0541] T / C=(V T末 / V T0 ) / (V C末 / V C0 ).
[0542] (1) Efficacy testing of anti-human Her2 antibody-drug conjugates in the NCI-N87 model
[0543] NCI-N87 cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum at 37°C and 5% CO2. NCI-N87 cells were collected during the exponential growth phase, resuspended in PBS to an appropriate concentration, and inoculated subcutaneously into female Balb / c-nu mice to establish a gastric cancer model. When the average tumor volume reached approximately 150 mm, the cells were cultured in RPMI 1640 medium at 37°C and 5% CO2. 3 At approximately 14 days, the mice were randomly divided into the following groups according to tumor size: a vehicle control group (i.e., negative control, vehicle group) and a 1 mg / kg trastuzumab-K-18 group of the present invention. The mice were administered by tail vein injection (iv) on Day 0 and Day 7, for a total of two doses. After administration, the mice were weighed once a week and the major and minor diameters of the tumors were measured with a vernier caliper. The tumor volume was calculated according to the following formula: V = 0.5a × b 2 , where a and b represent the long diameter and short diameter of the tumor, respectively. Animal deaths were observed and recorded every day.
[0544] The ADC of this invention demonstrated significant tumor growth inhibition in the NCI-N87 gastric cancer xenograft model. Compared to the vehicle group, the tumor growth inhibition rate (TGI) of the 1 mg / kg trastuzumab-K-18 group was 164.99%. No animals died or experienced significant weight loss on Day 30, and no significant drug toxicity was observed. The ADC of this invention was well tolerated by mice during treatment. Detailed results are shown in Table 21, Figures 1 and 2.
[0545] Table 21 Human gastric cancer cell NCI-N87 CDX model
[0546] Note: TGI is tumor growth inhibition rate, T / C is relative tumor proliferation rate, the same below.
[0547] VI. Evaluation of the Antibody-Drug Conjugate's Inhibitory Effect on Tumor Growth in a Mouse Subcutaneous Xenograft Tumor Model
[0548] The preparations containing the ADC of the present invention were administered via tail vein injection to a CDX mouse model subcutaneously transplanted with human breast cancer cells JIMT-1. The tumor volume and animal body weight changes were measured once a week, and the tumor inhibition efficacy of the ADC of the present invention on tumor-bearing mice was calculated.
[0549] Test drug
[0550] Drug name, source, and preparation method: Take an appropriate amount of the ADC of the present invention, and dilute the stock solution with 0.9% NaCl injection to a dosing solution at a dose volume of 3 mg / kg. 0.9% NaCl injection is used as a vehicle control (Vehicle).
[0551] Experimental animals and cell lines
[0552] NOD SCID mice (Chengdu Yaokang Biotechnology Co., Ltd.)
[0553] Human breast cancer cells JIMT-1 (Nanjing Kebai)
[0554] Experimental grouping and evaluation methods
[0555] The average tumor volume was about 150 mm. 3 Tumor-bearing mice were randomly divided into groups (the number of groups was determined based on the sample size). The groups were administered 0.9% NaCl injection (hereinafter referred to as vehicle control) and the ADC of the present invention. The dosing frequency is described in the specific examples. The administration method was tail vein injection, and the administration volume was 10 ml / kg. Tumor diameter was measured with a vernier caliper once a week after administration, and tumor volume was calculated using the following formula: V = 0.5a × b 2 , where a and b represent the long and short diameters of the tumor, respectively. Animal mortality was recorded daily.
[0556] The tumor growth inhibition rate (TGI) was calculated using the following formula to evaluate the tumor inhibition efficacy of the ADC of the present invention:
[0557] V T末 >V T0 ,TGI(%)=[1-(V T末 -V T0 ) / (V C末 -V C0 )]*100% or V T末 ≤V T0 ,TGI(%)=[1-(V T末 -VT0) / VT0]*100%.
[0558] Where V T末 : Mean tumor volume of treatment group at the end of the experiment
[0559] V T0 : Mean tumor volume at the start of drug administration in the treatment group
[0560] V C末 : Mean tumor volume of negative control group at the end of the experiment
[0561] V C0 : Mean tumor volume of negative control group at the beginning of drug administration
[0562] The following formula was used to calculate the tumor relative proliferation rate T / C (%), which was used to evaluate the tumor inhibition efficacy of the ADC of the present invention:
[0563] T / C=(V T末 / V T0) / (V C末 / V C0 ).
[0564] (1) Efficacy testing of anti-human Her2 antibody-drug conjugates in the JIMT-1 model
[0565] JIMT-1 cells were cultured in DMEM containing 10% fetal bovine serum at 37°C and 5% CO2. JIMT-1 cells in the exponential growth phase were harvested, resuspended in PBS containing 50% Matrigel to an appropriate concentration, and inoculated subcutaneously into female NOD SCID mice to establish a breast cancer model. When the average tumor volume reached approximately 150 mm, the cells were inoculated with a 5% PBS solution containing 50% Matrigel. 3 Around 30 minutes later, the mice were randomly divided into groups according to the size of the tumor, in the following order: vehicle control group (i.e., negative control, Vehicle group), Trastuzumab-K-18 1 mg / kg group of the present invention, Trastuzumab-K-18 3 mg / kg, Trastuzumab-K-17 1 mg / kg group, and Trastuzumab-K-17 3 mg / kg group. Each group was injected by tail vein (iv), and the drug was administered on Day 0, for a total of 1 dose. After administration, the body weight of the mice was measured once a week, and the long and short diameters of the tumor were measured with a vernier caliper, and the tumor volume was calculated according to the following formula: V = 0.5a × b 2 , where a and b represent the long diameter and short diameter of the tumor, respectively. Animal deaths were observed and recorded every day.
[0566] The ADC of this invention demonstrated significant tumor growth inhibition in the JIMT-1 breast cancer xenograft model. Compared with the vehicle group, the tumor growth inhibition rates (TGI) of the 1 mg / kg trastuzumab-K-18, 3 mg / kg trastuzumab-K-18, 1 mg / kg trastuzumab-K-17, and 3 mg / kg trastuzumab-K-17 groups were 81.64%, 163.54%, 62.33%, and 139.31%, respectively. On Day 20, there were no animal deaths or significant weight loss in any treatment group, and no significant drug toxicity was observed. The ADC of this invention was well tolerated by mice during treatment. Detailed results are shown in Table 22, Figures 3 and 4.
[0567] Table 22 Human breast cancer cell JIMT-1CDX model
[0568] Note: TGI is tumor growth inhibition rate, T / C is relative tumor proliferation rate, the same below.
[0569] Although the specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and substitutions may be made to those details based on all the teachings disclosed, and these changes are all within the scope of protection of the present invention. The full scope of the present invention is given by the appended claims and any equivalents thereof.
Claims
1. A compound or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein the compound has a structure as shown in the following formula (I): in, Indicates a single bond or no chemical bond; R1, R2, R3, R4, R6 and R7 are each independently selected from hydrogen, -CN, halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1- 6 alkyl)2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl; the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl and heteroaryl are optionally substituted by one or more selected from -CN, halogen, -OH, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 substituted by aryl and 5-10 membered heteroaryl substituents; R5 is -(C=O)-D2-D3-X6, wherein D2 is -O-, -S- or -NR X -, where R X is hydrogen or C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl)2 and -CN; D3 is C 1-6 Alkylene, C 2-6 Alkenylene or C 2-6 Alkyne; the alkylene, alkenylene and alkynylene are optionally substituted by one or more selected from -CN, halogen, -OH, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 aryl and 5-10 membered heteroaryl substituents; X6 is selected from hydrogen, halogen, -OH, C 1-6 Alkoxy, -SH, -SC 1-6 Alkyl, -NH2, -NH(C 1-6 Alkyl) and -N(C 1-6 Alkyl)2, the C 1-6 The alkyl group is optionally substituted with one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -CN and C 1-6 Substitution of alkoxy groups; Y1 and Y2 are each independently -C(R8)2-, wherein R8 is each independently selected from hydrogen, -CN, halogen, -OH, -NH2, -NH(C 1- 6 alkyl), -N(C 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6- 10 Aryl and 5-10 membered heteroaryl, or two R8 attached to the same carbon atom together form =O; X1, X2 and X5 are each independently selected from substituted or unsubstituted C 1-6 Alkylene, -O-, -NR Y - and -S-; among which R Y Each occurrence is independently selected from hydrogen or optionally substituted by one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2 and -CN substituted C 1-6 alkyl; when When it represents a single bond, X4 is selected from substituted or unsubstituted C 1-6 Alkylene, -O-, -NR Y - and -S-; among which R Y Each occurrence is independently selected from hydrogen or optionally substituted by one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2 and -CN substituted C 1-6 alkyl; when When there is no chemical bond, X4 is selected from substituted or unsubstituted C 1-6 Alkyl, -OR Y 、-N(R Y )2 and -S-; wherein R Y Each occurrence is independently selected from hydrogen or optionally substituted by one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 alkyl C substituted with a substituent of -CN 1-6 alkyl; X3 for CR Z or N, where R Z is hydrogen or optionally substituted by one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2 and -CN substituted C 1-6 alkyl; And, when When it represents a single bond, R1 and R7 are methoxy, R2, R3, and R4 are all hydroxyl, Y1 and Y2 are all -(C=O)-, X1, X2, X4, and X5 are all O, X3 is N, D2 is NH, and D3 is ethylene, X6 is not NH2.
2. The compound of claim 1 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein: R1, R2, R3, R4, R6 and R7 are each independently selected from hydrogen, -CN, halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1- 6 alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy; the alkyl group, alkoxy group is optionally substituted by one or more selected from -CN, halogen, -OH, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 substituted by aryl and 5-10 membered heteroaryl substituents; Preferably, R1, R2, R3, R4, R6 and R7 are each independently selected from hydrogen, -OH, C 1-6 Alkyl and C 1-6 Alkoxy; the alkoxy is optionally substituted by one or more selected from -CN, halogen, -OH, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 substituted by aryl and 5-10 membered heteroaryl substituents; Further preferably, R1, R2, R3, R4, R6 and R7 are each independently selected from hydrogen, -OH, C 1-6 Alkyl and C 1-6 Alkoxy.
3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein: R5 is -(C=O)-D2-D3-X6, wherein D2 is -O-, -S- or -NR X -, where R X is hydrogen or C 1-6 Alkyl; D3 is C 1-6 Alkylene; the alkylene is optionally substituted by one or more selected from -CN, halogen, -OH, -NH2, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 substituted by aryl and 5-10 membered heteroaryl substituents; X6 is selected from -OH, C 1- 6-alkoxy, -SH, -SC 1-6 Alkyl, -NH2, -NH(C 1-6 Alkyl) and -N(C 1-6 Alkyl)2, the C 1-6 The alkyl group is optionally substituted with one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2, -CN and C 1-6 Substitution of alkoxy groups; Preferably, R5 is -(C=O)-D2-D3-X6, wherein D2 is -O-, -S- or -NR X -, where R X is hydrogen or C 1-6 Alkyl; D3 is C 1-6 Alkylene; X6 is selected from -OH, C 1-6 Alkoxy, -SH, -SC 1-6 Alkyl, -NH2, -NH(C 1-6 Alkyl) and -N(C 1-6 Alkyl)2.
4. The compound of any one of claims 1 to 3 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein: Y1 and Y2 are each independently -C(R8)2-, wherein R8 is each independently selected from hydrogen, -CN, halogen, -OH, -NH2, -NH(C 1- 6 alkyl), -N(C 1-6 Alkyl)2, C 1-6 Alkyl and C 1-6 Alkoxy, or two R8 attached to the same carbon atom together form =O; Preferably, Y1 and Y2 are both -(C=O)-.
5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein: X1, X2, X4 and X5 are each independently selected from substituted or unsubstituted C 1-6 Alkylene, -O- or -NR Y ; where R Y Each occurrence is independently selected from hydrogen or optionally substituted by one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2 and -CN substituted C 1-6 alkyl; Preferably, X1, X2, X4 and X5 are all -O-.
6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein: when When it represents a single bond, X4 is a substituted or unsubstituted C 1-6 Alkylene or -O-; Preferably, X4 is selected from -O-; when When there is no chemical bond, X4 is selected from substituted or unsubstituted C 1-6 Alkyl, -OR Y ; where R Y Each occurrence is independently selected from hydrogen or optionally substituted by one or more selected from halogen, -OH, -NH2, -NH(C 1-6 Alkyl), -N(C 1-6 Alkyl)2 and -CN substituted C 1-6 Alkyl; preferably, X4 is selected from -OH.
7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein: X3 for CR Z or N, where R Z is selected from hydrogen or C optionally substituted by one or more substituents selected from halogen, -OH, -NH2 and -CN 1-6 alkyl; Preferably, X3 is N.
8. The compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein the compound has a structure as shown in the following formula (III)-1 or (III)-2: in, X1-X5, R1-R7, Y1 and Y2 are as described in any one of claims 1 to 7.
9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein the compound has a structure as shown in the following formula (IV)-1 or (IV)-2: in, R5 is as described in claim 1 or 3.
10. The compound of any one of claims 1 to 9 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, wherein the compound is selected from the following structures:
11. An antibody drug conjugate comprising a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled product, metabolite or prodrug fragment thereof.
12. A pharmaceutical composition comprising the compound of any one of claims 1 to 10 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof or the antibody-drug conjugate of claim 11, and one or more pharmaceutical excipients.
13. Use of the compound according to any one of claims 1 to 10 or its pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite or prodrug, the antibody drug conjugate according to claim 11 or the pharmaceutical composition according to claim 12 in the preparation of a drug for treating cancer or tumor.
14. The use of claim 13, wherein the cancer or tumor is a solid tumor or a hematological malignancy; for example, selected from gastric cancer, breast cancer, lung cancer (eg, non-small cell lung cancer, specifically lung adenocarcinoma) and urothelial carcinoma.
15. The compound of any one of claims 1 to 10 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, the antibody drug conjugate of claim 11 or the pharmaceutical composition of claim 12 for use in treating cancer or tumors.
16. The compound of claim 15 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope-labeled substance, metabolite or prodrug thereof, an antibody drug conjugate or a pharmaceutical composition thereof, wherein the cancer or tumor is a solid tumor or a hematological malignancy; for example, selected from gastric cancer, breast cancer, lung cancer (e.g., non-small cell lung cancer, specifically lung adenocarcinoma) and urothelial carcinoma.
17. A method for treating cancer or tumors, comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, nitrogen oxide, isotope label, metabolite or prodrug thereof, an antibody drug conjugate according to claim 11 or a pharmaceutical composition according to claim 12 to an individual in need thereof.
18. The method of claim 17, wherein the cancer or tumor is a solid tumor or a hematological malignancy; for example, selected from gastric cancer, breast cancer, lung cancer (eg, non-small cell lung cancer, particularly lung adenocarcinoma) and urothelial carcinoma.
Citation Information
Patent Citations
Anti-lgr5 antibodies and immunoconjugates
CN104411721A
Antibody drug conjugates
CN107635405A
Antibody drug conjugate as well as preparation method, intermediate, drug composition and application thereof
CN108210935A
Ligand-drug-conjugate comprising single molecular weight polysarcosine
CN111542344A
ROR1 antibody immunoconjugates
CN111587124A
Cited By
Polycyclic compound, and preparation method therefor and use thereof
WO2026098309A1
Anthracycline compound, antibody-drug conjugate thereof, preparation method therefor, and use thereof
WO2026145450A1
